


FORM PTO-1390 (REV 11-98)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 3525-96
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO (If known, see 37 C.F.R. 1.5) 09/623709	
INTERNATIONAL APPLICATION NO. PCT/SE00/01253	INTERNATIONAL FILING DATE 15 June 2000	PRIORITY DATE CLAIMED 16 June 1999	
TITLE OF INVENTION NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS			
APPLICANT(S) FOR DO/EO/US BJORE et al			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to DELAY national examination procedures (35 U.S.C. 371(f) until the expiration of the applicable time limit set in 35 U.S.C. 371(b) Articles 22 and 39(1).</p> <p>4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>5a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>5b. <input type="checkbox"/> has been transmitted by the International Bureau.</p> <p>5c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>7a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>7b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>7c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>7d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>			
Items 11. To 16. Below concern document(s) or information included:			
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.</p> <p>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input type="checkbox"/> Other items or information.</p>			

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)	INTERNATIONAL APPLICATION NO	ATTORNEY'S DOCKET NUMBER			
09/623709		PCT/SE00/01253		3525-96	
17. <input checked="" type="checkbox"/> The following fees are submitted:			CALCULATIONS PTO USE ONLY		
BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5):					
-- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00					
-- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00					
-- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO \$690.00					
-- International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00					
-- International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =					
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).					
CLAIMS		NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims		26	-20 =	6	X \$18.00
Independent Claims		1	-3 =	0	X \$78.00
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)				\$260.00	
TOTAL OF ABOVE CALCULATIONS = \$ 1078.00					
Reduction by 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 C.F.R. 1.9, 1.27, 1.28). 0.00					
SUBTOTAL = \$ 1078.00					
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)). + 0.00					
TOTAL NATIONAL FEE = \$ 1078.00					
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property + \$ 40.00					
Fee for Petition to Revive Unintentionally Abandoned Application (\$1210.00 - Small Entity = \$605.00) \$ 0.00					
TOTAL FEES ENCLOSED = \$ 1118.00					
Amount to be: refunded \$ Charged \$					
<input checked="" type="checkbox"/> A check in the amount of \$1118.00 to cover the above fees is enclosed. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees. A duplicate copy of this form is enclosed. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A <u>duplicate</u> copy of this form is enclosed. <input type="checkbox"/> The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.					
NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
 Leonard C. Mitchard NAME					
NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8 th Floor Arlington, Virginia 22201 Telephone: (703) 816-4000					
29,009 September 7, 2000					
REGISTRATION NUMBER Date					

SEND ALL CORRESPONDENCE TO:

NIXON & VANDERHYE P.C.
1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201
Telephone: (703) 816-4000

SIGNATURE

Leonard C. Mitchard

NAME

29,009

September 7, 2000

REGISTRATION NUMBER Date

09/623709
533 Rec'd PCT/PTO 07 SEP 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BJORE et al

Atty. Ref.: 3525-96

Serial No. Unassigned

Group:

Filed: September 7, 2000

Examiner:

For: NEW BISPIDINE COMPOUNDS USEFUL IN
THE TREATMENT OF CARDIAC
ARRYTHMIAS

* * * * *

September 7, 2000

Assistant Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the above application as follows:

IN THE CLAIMS

Claim 3, line 1, delete "or Claim 2".

Claim 4, line 1, delete "any one of the preceding claims" and replace by

--claim 1--.

Claim 5, line 1, delete "any one of the preceding claims" and replace by

--claim 1--.

Claim 6, line 1, delete "any one of the preceding claims" and replace by

--claim 1--.

Claim 7, line 1, delete "any one of the preceding claims" and replace by

--claim 1--

Claim 8, line 1, delete "any one of the preceding claims" and replace by

--claim 1--

Claim 9, line 1, delete "any one of the preceding claims" and replace by

--claim 1--

Claim 10, line 1, delete "any one of the preceding claims" and replace by

--claim 1--

Claim 11, line 1, delete "any one of the preceding claims" and replace by

--claim 1--

Claim 12, line 1, delete "any one of the preceding claims" and replace by

--claim 1--

Claim 13, line 1, delete "any one of the preceding claims" and replace by

--claim 1--

Claim 14, lines 1-2, delete "any one of Claims 1 to 13" and replace by

--claim 1--

Claim 15, lines 3-4, delete "any one of Claims 1 to 13" and replace by

--claim 1--

Claim 16, line 1, delete "any one of Claims 1 to 13" and replace by

--claim 1--

Claim 17, line 1, delete "any one of Claims 1 to 13" and replace by

--claim 1--

Claim 18, line 1, delete "any one of Claims 1 to 13" and replace by

--claim 1--

Claim 20, line 3, delete "any one of Claims 1 to 13" and replace by


--claim 1--

REMARKS

The above amendments have been made to place the application in a more traditional format.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 

Leonard C. Mitchard
Reg. No. 29,009

LCM:iks
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS

Field of the Invention

5

This invention relates to novel pharmaceutically useful compounds, in particular compounds which are useful in the treatment of cardiac arrhythmias.

10 Background and Prior Art

Cardiac arrhythmias may be defined as abnormalities in the rate, regularity, or site of origin of the cardiac impulse or as disturbances in conduction which causes an abnormal sequence of activation. Arrhythmias may be 15 classified clinically by means of the presumed site of origin (i.e. as supraventricular, including atrial and atrioventricular, arrhythmias and ventricular arrhythmias) and/or by means of rate (i.e. bradyarrhythmias (slow) and tachyarrhythmias (fast)).

20 In the treatment of cardiac arrhythmias, the negative outcome in clinical trials (see, for example, the outcome of the Cardiac Arrhythmia Suppression Trial (CAST) reported in New England Journal of Medicine, 321, 406 (1989)) with "traditional" antiarrhythmic drugs, which act primarily by slowing the conduction velocity (class I antiarrhythmic drugs), has prompted 25 drug development towards compounds which selectively delay cardiac repolarization, thus prolonging the QT interval. Class III antiarrhythmic drugs may be defined as drugs which prolong the trans-membrane action potential duration (which can be caused by a block of outward K⁺ currents

or from an increase of inward ion currents) and refractoriness, without affecting cardiac conduction.

One of the key disadvantages of hitherto known drugs which act by delaying 5 repolarization (class III or otherwise) is that they all are known to exhibit a unique form of proarrhythmia known as *torsades de pointes* (turning of points), which may, on occasion be fatal. From the point of view of safety, the minimisation of this phenomenon (which has also been shown to be exhibited as a result of administration of non-cardiac drugs such as 10 phenothiazines, tricyclic antidepressants, antihistamines and antibiotics) is a key problem to be solved in the provision of effective antiarrhythmic drugs.


Antiarrhythmic drugs based on bispidines (3,7-diazabicyclo[3.3.1]nonanes), are known from *inter alia* international patent application WO 91/07405, 15 European patent applications 306 871, 308 843 and 655 228 and US patents 3,962,449, 4,556,662, 4,550,112, 4,459,301 and 5,468,858, as well as journal articles including *inter alia* J. Med. Chem. **39**, 2559, (1996), Pharmacol. Res., **24**, 149 (1991), Circulation, **90**, 2032 (1994) and Anal. Sci. **9**, 429, (1993). Known bispidine-based antiarrhythmic compounds 20 include bisaramil (3-methyl-7-ethyl-9 α ,4'-(Cl -benzoyloxy)-3,7-diazabicyclo[3.3.1]nonane), tedisamil (3',7'-bis(cyclopropylmethyl)spiro-(cyclopentane-1,9')-3,7-diazabicyclo[3.3.1]nonane), SAZ-VII-22 (3-(4-chlorobenzoyl)-7-isopropyl-3,7-diazabicyclo[3.3.1]nonane), SAZ-VII-23 (3-benzoyl-7-isopropyl-3,7-diazabicyclo[3.3.1]nonane), GLG-V-13 (3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nonane), KMC- 25 IV-84 (7-[4'-(1H-imidazolo-1-yl)benzenesulfonyl]-3-isopropyl-3,7-diazabicyclo[3.3.1]nonane dihydroperchlorate and ambasilide (3-(4-aminobenzoyl)-7-benzyl-3,7-diazabicyclo[3.3.1]nonane).

We have surprisingly found that a novel group of bispidine-based compounds exhibit electrophysiological activity, preferably class III electrophysiological activity, and are therefore expected to be useful in the treatment of cardiac arrhythmias.

5

Disclosure of the Invention

According to the invention there is provided compounds of formula I,



10

wherein

R^1 represents C_{1-12} alkyl, $-(CH_2)_a$ -aryl, or $-(CH_2)_a$ -Het¹ (all of which are optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, halo, cyano, nitro, C_{1-4} alkyl and/or C_{1-4}

15

alkoxy);

a represents 0, 1, 2, 3, or 4;

Het¹ represents a five to ten-membered heterocyclic ring containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

X represents O or S;

R^{5a} and R^{5b} independently represent H or C₁₋₃ alkyl;

5

R² and R³ independently represent H, C₁₋₄ alkyl (optionally substituted and/or terminated with one or more nitro or cyano groups), OR⁷, N(R^{7a})R^{7b}, OC(O)R⁸ or together form -O-(CH₂)₂-O-, -(CH₂)₃-, -(CH₂)₄- or -(CH₂)₅-;

10 R⁷ and R⁸ independently represent H, C₁₋₆ alkyl or -(CH₂)_b-aryl (which latter two groups are optionally substituted and/or terminated by one or more substituents selected from -OH, halo, cyano, nitro, C₁₋₄ alkyl and/or C₁₋₄ alkoxy);

R^{7a} and R^{7b} independently represent H or C₁₋₆ alkyl;

15 b represents 0, 1, 2, 3 or 4;

R⁴ represents H or C₁₋₆ alkyl;

D represents H, C₁₋₄ alkyl, -OH, or -(CH₂)_cN(R¹⁰)(R¹¹);

20 c represents 0, 1, 2, 3 or 4;

R¹⁰ represents H, C₁₋₆ alkyl, -(CH₂)_d-aryl, -C(NH)NH₂, -S(O)₂R¹³, -[C(O)]_eN(R¹⁴)(R¹⁵), -C(O)R¹⁶ or -C(O)OR¹⁷;

e represents 1 or 2;

25 R¹¹ represents H, C₁₋₆ alkyl, -C(O)R¹⁸ or -(CH₂)_f-aryl (which latter group is optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, cyano, halo, amino, nitro, C₁₋₆ alkyl and/or C₁₋₆ alkoxy);

R¹⁴, R¹⁵, R¹⁶, R¹⁷ and R¹⁸ independently represent H, C₁₋₆ alkyl, Het² or

$-(CH_2)_g$ -aryl (which latter three groups are optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

5 R^{13} represents C_{1-6} alkyl, aryl or $-(CH_2)_h$ -aryl (all of which are all optionally substituted and/or terminated (as appropriate) by one or more substituents chosen from halo, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

d, f, g and h independently represent 0, 1, 2, 3 or 4;

10 Het² represents a five to ten-membered heterocyclic ring containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

15 R^6 represents one or more optional substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl (optionally terminated by $-N(H)C(O)OR^{18a}$), C_{1-6} alkoxy, $-C(O)N(H)R^{19}$, $-NHC(O)N(H)R^{20}$, $-N(H)S(O)_2R^{21}$ and/or -OS(O)₂R²²;

R^{19} and R^{20} independently represent H or C_{1-6} alkyl;

R^{18a} , R^{21} and R^{22} independently represent C_{1-6} alkyl;

20 A represents a single bond, C_{1-6} alkylene, $-N(R^{23})(CH_2)_j-$, $-O(CH_2)_j-$ or $-(CH_2)_jC(H)(OR^{23})(CH_2)_k-$ (in which latter three groups, the $-(CH_2)_j-$ group is attached to the bispidine nitrogen atom, and which latter four groups are all optionally substituted by one or more OH groups);

25 B represents a single bond, C_{1-4} alkylene, $-(CH_2)_mN(R^{24})-$, $-(CH_2)_mS(O)_n-$, $-(CH_2)_mO-$ (in which three latter groups, the $-(CH_2)_m-$ group is attached to the carbon atom bearing D and R⁴), $-C(O)N(R^{24})-$ (in which latter group, the $-C(O)-$ group is attached to the carbon atom bearing D and R⁴), $-N(R^{24})C(O)O(CH_2)_m-$ or $-N(R^{24})(CH_2)_m-$ (in which latter two groups, the $N(R^{24})$ group is attached to the carbon atom bearing D and R⁴);

j, k and m independently represent 0, 1, 2, 3 or 4;

n represents 0, 1 or 2;

R²³ represents H, C₁₋₆ alkyl or C(O)R²⁵;

R²⁴ represents H or C₁₋₆ alkyl;

R²⁵ represents H, C₁₋₆ alkyl, Het³ or -(CH₂)_p-aryl (which latter two groups are optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, cyano, halo, amino, nitro, C₁₋₆ alkyl and/or C₁₋₆ alkoxy);

Het³ represents a five to ten-membered heterocyclic ring containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

p represents 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable derivative thereof.

provided that:

(a) when D represents either H or -OH, and R^{5a} and R^{5b} both represent H, then at least one of R² and R³ represents OR⁷, OC(O)R⁸ or C₁₋₄ alkyl, which alkyl group is substituted and/or terminated with one or more nitro or cyano groups; and

(b) when D represents -OH or -(CH₂)_cN(R¹⁰)R¹¹ in which c represents 0, then:-

(i) A does not represent -N(R²³)(CH₂)_j-, -O(CH₂)_j- or -(CH₂)_jC(H)(OR²³)(CH₂)_k- (in which k is 0); and/or

(ii) m does not represent 0 when B represents -(CH₂)_mN(R²⁴)-, -(CH₂)_mS(O)_n- or -(CH₂)_mO-,

which compounds are referred to hereinafter as "the compounds of the invention".

Aryl groups that may be mentioned include C_{6-10} aryl groups, such as phenyl, naphthyl and the like. Oxyaryl groups that may be mentioned include C_{6-10} oxyaryl groups, such as oxyphenyl (phenoxy), oxynaphthyl (naphthoxy) and the like. When substituted, aryl and aryloxy groups are 5 preferably substituted by between one and three substituents.

Het¹, Het² and Het³ groups that may be mentioned include those containing 1 to 4 heteroatoms (selected from the group oxygen, nitrogen 10 and/or sulfur) and in which the total number of atoms in the ring system is between five and ten. Het (Het¹, Het² and Het³) groups may be wholly/partly aromatic in character and may be bicyclic. Heterocyclic groups that may be mentioned include morpholinyl, thiazolyl, oxazolyl, isoxazolyl, cinnolinyl, quinazolinyl, phthalazinyl, purinyl, benzimidazolyl, 15 pyrimidinyl, piperazinyl, pyrazinyl, piperidinyl, pyridinyl, pyrrolinyl, pyrrolidinyl, pyrrolidinonyl, triazolyl, imidazolyl, quinolinyl, isoquinolinyl, dioxanyl, benzodioxanyl, benzodioxolyl, benzodioxepanyl, benzomorpholinyl, indolyl, pyrazolyl, pyrrolyl, benzothiophenyl, thiophenyl, chromanyl, thiochromanyl, benzofuranyl, pyranyl, 20 tetrahydropyranyl, tetrahydrofuranyl, furanyl and the like. Values of Het² that may be mentioned include pyrrolidinonyl (e.g. 2-pyrrolidinon-5-yl). Substituents on Het (Het¹, Het² and Het³) groups may, where appropriate, 25 be located on any atom in the ring system including a heteroatom. The point of attachment of Het (Het¹, Het² and Het³) groups may be *via* any atom in the ring system including (where appropriate) a heteroatom. Het (Het¹, Het² and Het³) groups may also optionally be in the N- or S- oxidised form.

Pharmaceutically acceptable derivatives include salts and solvates. Salts which may be mentioned include acid addition salts. Pharmaceutically acceptable derivatives also include C₁₋₄ alkyl quaternary ammonium salts and N-oxides, provided that, when a N-oxide is present:

- 5 (a) no Het (Het¹, Het², Het³) groups contain an unoxidised S-atom;
- (b) X does not represent S; and/or
- (c) n does not represent 0, when B represents -(CH₂)_mS(O)_n⁻.

10 The compounds of the invention may exhibit tautomerism. All tautomeric forms and mixtures thereof are included within the scope of the invention.

The compounds of the invention may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism. Diastereoisomers may be separated using conventional techniques, e.g. 15 chromatography or fractional crystallisation. The various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques. Alternatively the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will 20 not cause racemisation or epimerisation, or by derivatisation, for example with a homochiral acid followed by separation of the diastereomeric esters by conventional means (e.g. HPLC, chromatography over silica). All stereoisomers are included within the scope of the invention.

25 Alkyl groups that R¹, R², R³, R⁴, R^{5a}, R^{5b}, R⁶, R⁷, R^{7a}, R^{7b}, R⁸, R¹⁰, R¹¹, R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R^{18a}, R¹⁹, R²⁰, R²¹, R²², R²³, R²⁴, R²⁵ and D may represent, and with which R¹, R⁷, R⁸, R¹¹, R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R²⁵ may be substituted; and alkoxy groups that R⁶ may represent, and with which R¹, R⁷, R⁸, R¹¹, R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R²⁵ may be

substituted, may be linear or, when there is a sufficient number (i.e. three) of carbon atoms, be branched and/or cyclic. Further, when there is a sufficient number (i.e. four) of carbon atoms, such alkyl and alkoxy groups may also be part cyclic/acyclic. Such alkyl and alkoxy groups may also be saturated or, when there is a sufficient number (i.e. two) of carbon atoms, be unsaturated and/or interrupted by oxygen and/or substituted by one or more fluoro groups.

Alkylene groups that A and B may represent, and -(CH₂)- containing groups that R¹, R² and R³ (together), R⁷, R⁸, R¹⁰, R¹¹, R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R²⁵, A, B and D may include, may be linear or, when there is a sufficient number (i.e. two) of carbon atoms, be branched. Such alkylene groups and -(CH₂)- containing chains may also be saturated or, when there is a sufficient number (i.e. two) of carbon atoms, be unsaturated and/or interrupted by oxygen.

As used herein, the term "halo" includes fluoro, chloro, bromo or iodo.

Abbreviations are listed at the end of this specification.

According to a further aspect of the invention there is provided compounds of formula I as hereinbefore defined, but with the further provisos that:

- (a) when A represents -N(R²³)(CH₂)_j- or -O(CH₂)_j-, then j does not represent 0 or 1; and
- (b) when D represents -OH or -(CH₂)_cN(R¹⁰)R¹¹ in which c represents 0, then B does not represent -N(R²⁴)C(O)O(CH₂)_m- or -N(R²⁴)(CH₂)_m-.

Preferred compounds of the invention include those in which:

R¹ represents optionally substituted -(CH₂)_a-phenyl, in which a is 0, 1, 2 or 3, or optionally substituted, optionally unsaturated, linear, branched or cyclic, C₁₋₁₈ alkyl (which latter group may also be interrupted by an oxygen atom);

5 R² represents H, OR⁷, -CH₂NO₂, -OC(O)R⁸, or together with R³ represents -O-(CH₂)₂-O-;

R³ represents H, OR⁷, C₁₋₄ alkyl or together with R² represents -O-(CH₂)₂-O-;

R⁴ represents H or C₁₋₂ alkyl;

10 R^{5a} and R^{5b} either both represent H or both represent methyl;

R⁶ represents one or more substituents selected from C₁₋₆ alkyl, cyano, nitro, amino or C(O)N(H)R¹⁹ or -N(H)S(O)₂R²¹;

X represents O;

A represents a single bond or linear, or branched, C₁₋₄ alkylene (which group is also optionally interrupted by O);

15 B represents a single bond, C₁₋₄ alkylene, -(CH₂)_mO- or -(CH₂)_mN(R²⁴)- (in which latter two cases m is 1, 2 or 3);

when the bispidine nitrogen bearing A optionally bears a C₁₋₄ alkyl group, thus forming a quaternary ammonium salt, the alkyl group is a methyl group.

When D represents -(CH₂)_cN(R¹⁰)(R¹¹), preferred compounds of the invention include those in which:

c represents 0, 1 or 2;

25 R¹⁰ represents H, C₁₋₄ alkyl, -C(O)R¹⁶ (in which R¹⁶ is H, C₁₋₃ alkyl or Het²), -C(O)OR¹⁷ (in which R¹⁷ is C₁₋₅ alkyl, phenyl or C₁₋₃ alkylphenyl), -C(NH)NH₂ or -[C(O)]_e-N(H)R¹⁵ (in which R¹⁵ is H or C₁₋₃ alkyl);

R¹¹ represents H.

More preferred compounds of the invention include those in which:

R¹ represents phenyl, C₁₋₂ alkylphenyl or linear or branched C₂₋₆ alkyl (all of which are optionally substituted with one or more cyano, methyl and/or halo groups);

5 R² represents H, OR⁷ (in which R⁷ is H or C₁₋₂ alkyl), -CH₂NO₂ or -OC(O)R⁸ (in which R⁸ is C₁₋₃ alkyl or optionally substituted phenyl);

R³ represents H, OR⁷ (in which R⁷ is H or C₁₋₂ alkyl) or methyl;

R⁴ represents methyl or, preferably, H;

R⁶ represents cyano, preferably in the *para* position relative to B;

10 A represents a single bond or C₁₋₂ alkylene (e.g. -CH₂-);

B represents a single bond, -(CH₂)_mN(H)- or -(CH₂)_mO- (in which latter two cases m is 1 or 2); and

D represents H, OH, -CH₂NH₂, -NHR¹⁰ (in which R¹⁰ is H, C₁₋₂ alkyl, -C(O)H, -[C(O)]₂NH₂, -C(NH)NH₂, -C(O)N(H)R¹⁵ (where R¹⁵ is H or C₁₋₂ alkyl), -C(O)[2-pyrrolidin-5-yl] or -C(O)OR¹⁷ (in which R¹⁷ is C₁₋₄ alkyl or benzyl)).

Preferred compounds of the invention include the compounds of the Examples described hereinafter.


20

Preparation

According to the invention there is also provided a process for the preparation of compounds of formula I which comprises:

25

(a) reaction of a compound of formula II,




wherein R^2 , R^3 , R^4 , R^{5a} , R^{5b} , R^6 , A, B and D are as hereinbefore defined with a compound of formula III,




wherein L^1 represents a leaving group, such as Hal, imidazolyl or $-OC(O)XR^1$, Hal represents Cl, Br or I, and R^1 and X are as hereinbefore defined, for example at or above room temperature in the presence of a suitable base (e.g. aqueous $NaOH$, K_2CO_3 or triethylamine) and an appropriate organic solvent (e.g. CH_2Cl_2 , THF, acetonitrile, toluene, or mixtures of such solvents);

10 (b) for compounds of formula I in which A represents CH_2 and D represents $-OH$ or $N(H)R^{10}$, reaction of a compound of formula IV,




wherein R¹, R², R³, R^{5a}, R^{5b} and X are as hereinbefore defined, with a compound of formula V,




wherein Y represents O or N(R¹⁰) and R⁴, R⁶, R¹⁰ and B are as hereinbefore defined, for example at elevated temperature (e.g. 60°C to reflux) in the presence of a suitable solvent (e.g. a lower alkyl alcohol (e.g. IPA), acetonitrile, or a mixture of a lower alkyl alcohol and water);

(c) reaction of a compound of formula IV, as hereinbefore defined, with a compound of formula VI,



wherein L^2 represents a leaving group (e.g. mesylate, tosylate or Hal, where Hal is as hereinbefore defined) and R^4 , R^6 , A, B and D are as hereinbefore defined, for example at elevated temperature (e.g. between 5 35°C and reflux temperature) in the presence of a suitable base (e.g. triethylamine or K_2CO_3) and an appropriate organic solvent (e.g. acetonitrile or dimethylsulfoxide);

10 (d) for compounds of formula I in which D represents H or OH and R^4 represents H, reduction of a compound of formula VII,




15 wherein R^1 , R^2 , R^3 , R^{5a} , R^{5b} , R^6 , A, B and X are as hereinbefore defined, in the presence of a suitable reducing agent and under appropriate reaction

conditions; for example, for formation of compounds of formula I in which D represents -OH, reduction may be performed under mild reaction conditions in the presence of e.g. sodium borohydride and an appropriate organic solvent (e.g. THF); and for formation of compounds of formula I in which D represents H, reduction may be performed by activating the relevant C=O group using an appropriate agent (such as tosylhydrazine) in the presence of a suitable reducing agent (e.g. sodium borohydride or sodium cyanoborohydride) and an appropriate organic solvent (e.g. a lower alkyl alcohol);

10

(e) for compounds of formula I in which R² and R³ both represent H, reduction of a corresponding compound of formula VIII,



15

wherein R¹, R⁴, R^{5a}, R^{5b}, R⁶, A, B, D and X are as hereinbefore defined, and in which the bridgehead C=O group may be activated using an appropriate agent, such as tosylhydrazine, in the presence of a suitable reducing agent (e.g. sodium borohydride or sodium cyanoborohydride) and an appropriate organic solvent (e.g. a lower alkyl alcohol), or under standard Wolff-Kischner conditions known to those skilled in the art; when

the C=O group is activated, the activation step may be carried out at between room and reflux temperature in the presence of an appropriate organic solvent (e.g. a lower alkyl alcohol such as methanol, ethanol or IPA), whereafter the reducing agent may be added to the reaction mixture 5 and the reduction carried out at between 60°C and reflux, advantageously in the presence of a suitable organic acid (e.g. acetic acid);


10 (f) for compounds of formula I in which one of R² and R³ represents H and the other represents -OH, reduction of a corresponding compound of formula VIII, as hereinbefore defined, in the presence of a mild reducing agent, e.g. sodium borohydride, and an appropriate organic solvent (e.g. a lower alcohol such as methanol or ethanol);

15 (g) for compounds of formula I in which R² and/or R³ represents OC(O)R⁸ and R⁸ is as hereinbefore defined, coupling of a corresponding compound of formula I in which R² and/or R³ (as appropriate) represents OH and a compound of formula VIIA,




20 wherein R⁸ is as hereinbefore defined, for example at ambient temperature (e.g. 25°C) in the presence of a suitable coupling agent (e.g. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide), an appropriate catalyst (e.g. 4-dimethylaminopyridine) and a reaction-inert organic solvent (e.g. THF);

25 (h) for compounds of formula I in which D represents -(CH₂)_cNH₂, reduction of a corresponding compound of formula IX,



wherein c, R¹, R², R³, R⁴, R^{5a}, R^{5b}, R⁶, A, B and X are as hereinbefore defined, for example by hydrogenation at a suitable pressure in the presence of a suitable catalyst (e.g. palladium on carbon) and an appropriate solvent (e.g. a water-ethanol mixture);

(i) for compounds of formula I in which D represents -N(R¹¹)C(O)NH(R¹⁵), in which R¹¹ and R¹⁵ are as hereinbefore defined, except that R¹¹ does not represent C(O)R¹⁸, reaction of a corresponding compound of formula I in which D represents -N(R¹¹)H, in which R¹¹ is as hereinbefore defined except that it does not represent C(O)R¹⁸ in which R¹⁸ is as hereinbefore defined, with a compound of formula X,



wherein R¹⁵ is as hereinbefore defined, for example at ambient temperature (e.g. 25°C) in the presence of a suitable solvent (e.g. benzene);

(j) for compounds of formula I in which D represents -N(H)[C(O)]₂NH₂, reaction of a corresponding compound of formula I in which D represents

-NH₂ with oxalic acid diamide, for example at between -10 and 25°C in the presence of a suitable coupling agent (e.g. 1-(3-dimethylamino-propyl)-3-ethylcarbodiimide), an appropriate activating agent (e.g. 1-hydroxybenzotriazole), a suitable base (e.g. triethylamine) and a reaction-inert organic solvent (e.g. DMF);

(k) for compounds of formula I in which D represents -N(R¹¹)C(O)R¹⁶, in which R¹¹ and R¹⁶ are as hereinbefore defined, except that R¹¹ does not represent C(O)R¹⁸, reaction of a corresponding compound of formula I in which D represents -N(R¹¹)H, in which R¹¹ is as hereinbefore defined except that it does not represent C(O)R¹⁸, with a compound of formula XI,



wherein R^x represents a suitable leaving group, such as C₁₋₄ alkoxy, Hal (e.g. Cl, Br) or *p*-nitrophenyl and R¹⁶ is as hereinbefore defined, for example at between ambient and reflux temperature in the presence of a suitable solvent (e.g. methanol or DMSO) and (as appropriate) a suitable base (e.g. K₂CO₃ or TEA);

(l) for compounds of formula I in which D represents -N(H)R¹⁰ and R¹⁰ is as hereinbefore defined except that it does not represent H or -C(NH)NH₂, reaction of a corresponding compound of formula I wherein D represents -NH₂ with a compound of formula XIA,



wherein R^{10a} represents R¹⁰ as hereinbefore defined, except that it does not represent H or -C(NH)NH₂ and L¹ is as hereinbefore defined, for example under conditions that are known to those skilled in the art;

(m) for compounds of formula I which are bispidine-nitrogen N-oxide derivatives, oxidation of the corresponding bispidine nitrogen of a


corresponding compound of formula I, in the presence of a suitable oxidising agent (e.g. *m*-chloroperbenzoic acid), for example at 0°C in the presence of a suitable organic solvent (e.g. DCM);

5 (n) for compounds of formula I which are C_{1-4} alkyl quaternary ammonium salt derivatives, in which the alkyl group is attached to a bispidine nitrogen, reaction, at the bispidine nitrogen, of a corresponding compound of formula I with a compound of formula XII,




10 wherein R^a represents C_{1-4} alkyl and Hal is as hereinbefore defined, for example at room temperature in the presence of an appropriate organic solvent (e.g. DMF), followed by purification (using e.g. HPLC) in the presence of a suitable counter-ion provider (e.g. NH_4OAc);

15 (o) for compounds of formula I in which D and R^4 both represent H, A represents C_{1-6} alkylene, B represents $-N(R^{24})(CH_2)_m-$ and m and R^{24} are as hereinbefore defined, reaction of a compound of formula XIII,



20

wherein A^a represents C_{1-6} alkylene and R^1 , R^2 , R^3 , R^{5a} , R^{5b} , R^{24} and X are as hereinbefore defined with a compound of formula XIV,



wherein R⁶, m and Hal are as hereinbefore defined, for example at 40°C in the presence of a suitable organic solvent (e.g. acetonitrile);


5 (p) reaction of a compound of formula II, as hereinbefore defined, with a compound of formula XV,



wherein R¹ and X are as hereinbefore defined, in the presence of 1,1'-carbonyldiimidazole, for example by refluxing in the presence of a 10 suitable organic solvent (e.g. THF);


(q) for compounds of formula I in which one of R² and R³ represents -NH₂ and the other represents H, reduction of a compound of formula XVA,

15



wherein R^1 , R^4 , R^{5a} , R^{5b} , R^6 , A, B, D and X are as hereinbefore defined, in the presence of a suitable reducing agent (e.g. $LiAlH_4$), for example under conditions that are well known to those skilled in the art;

5 (r) for compounds of formula I in which one or both of R^2 and R^3 represent $-N(R^{7a})R^{7b}$ in which one or both of R^{7a} and R^{7b} represents C_{1-6} alkyl, alkylation of a corresponding compound of formula I in which R^2 and/or R^3 represent $-N(R^{7a})R^{7b}$ (as appropriate) in which R^{7a} and/or R^{7b} (as appropriate) represent H, using a compound of formula XVB,




wherein R^{7c} represents C_{1-6} alkyl and L^1 is as hereinbefore defined, for example under conditions that are well known to those skilled in the art; or

15 (s) conversion of one R^6 substituent to another using techniques well known to those skilled in the art.

Compounds of formula II may be prepared by reaction of a compound of formula XVI,


20



wherein R^2 , R^3 , R^{5a} and R^{5b} are as hereinbefore defined, with a compound of formula VI as hereinbefore defined, for example as described

hereinbefore for synthesis of compounds of formula I (process step (c)), or, in the case of compounds of formula II wherein A represents CH_2 and D represents OH or $\text{N}(\text{R}^{10})\text{H}$, with a compound of formula V, for example as described hereinbefore for synthesis of compounds of formula I (process step (b)).

Compounds of formula II in which R² and R³ both represent H may be prepared by reduction of a compound of formula XVII,



10 wherein R^4 , R^{5a} , R^{5b} , R^6 , A, B and D are as hereinbefore defined, and in which the C=O group may be activated using an appropriate agent, such as tosylhydrazine, for example as described hereinbefore for synthesis of compounds of formula I (process step (e)).

15 Compounds of formula II in which R² represents OH and R³ represents optionally substituted C₁₋₄ alkyl, may be prepared by reaction of a compound of formula XVII, or a protected derivative thereof, with a compound of formula XVIIA




20 wherein R^{3a} represents C₁₋₄ alkyl (optionally substituted and/or terminated with one or more cyano groups) and Hal is as hereinbefore defined, for

example at between -25°C and ambient temperature in the presence of a suitable solvent (e.g. diethyl ether).

Compounds of formula IV may be prepared by reaction of a compound of formula XVI, as hereinbefore defined, with a compound of formula III as hereinbefore defined, for example as described hereinbefore for synthesis of compounds of formula I (process step (a)).

Compounds of formula IV may alternatively be prepared by reaction of a compound of formula XVI, as hereinbefore defined, with a compound of formula XV, as hereinbefore defined, in the presence of 1,1'-carbonyldiimidazole, for example as described hereinbefore for synthesis of compounds of formula I (process step (p)).


Compounds of formula IV in which R² and R³ represent H may alternatively be prepared by reduction of a corresponding compound of formula XVIII,



wherein R¹, R^{5a}, R^{5b} and X are as hereinbefore defined, and in which the bridgehead C=O group may be activated using an appropriate agent, such as tosylhydrazine, for example as described hereinbefore for compounds of formula I (process step (e)).

Compounds of formula V may be prepared in accordance with techniques which are well known to those skilled in the art. For example, compounds of formula V in which:

5 (1) B represents $-\text{CH}_2\text{O}-$ and Y represents O may be prepared by reaction of a compound of formula XIX,




10 wherein R⁶ is as hereinbefore defined, with a compound of formula XX,



15 wherein R⁴ is as hereinbefore defined, for example at elevated temperature (e.g. between 60°C and reflux temperature) in the presence of a suitable base (e.g. K₂CO₃ or NaOH) and an appropriate organic solvent (e.g. acetonitrile or toluene/water), or as otherwise described in the prior art;


20 (2) B represents $-\text{CH}_2\text{O}-$ and Y represents O may alternatively be prepared by reaction of a compound of formula XIX, as hereinbefore defined, with a compound of formula XXI,



XXI

wherein R⁴ is as hereinbefore defined, for example between room temperature and elevated temperature (e.g. 40°C) in the presence of a 5 suitable base (e.g. K₂CO₃ or potassium ethoxide) and an appropriate organic solvent (e.g. acetonitrile or DMF);


(3) B represents a single bond, Y represents O and R⁴ represents H may be prepared by reduction of a compound of formula XXII,



10


wherein R⁶ is as hereinbefore defined, for example at between -15°C and room temperature in the presence of a suitable reducing agent (e.g. NaBH₄) and an appropriate organic solvent (e.g. THF), followed by an internal displacement reaction of the resultant intermediate, for 15 example at room temperature in the presence of a suitable base (e.g. K₂CO₃) and an appropriate organic solvent (e.g. acetonitrile);

(4) B represents C₁₋₄ alkylene, -(CH₂)_mN(R²⁴)-, -(CH₂)_mS(O)₂- or -(CH₂)_mO- (in which latter three groups m represents 1, 2, 3 or 4) and Y represents O may be prepared by oxidation of a compound of formula XXIII,



in which B^a represents a single bond, C_{1-3} alkylene, $-(CH_2)_{m-1}N(R^{24})-$, $-(CH_2)_{m-1}S(O)_2-$ or $-(CH_2)_{m-1}O-$ (in which latter three groups m represents 1, 2, 3 or 4) and R^{24} and R^6 are as hereinbefore defined, in the presence 5 of a suitable oxidising agent (e.g. *m*-chloroperbenzoic acid), for example by refluxing in the presence of a suitable organic solvent (e.g. dichloromethane); or


(5) B represents $-(CH_2)_mO-$, Y represents $N(R^{10})$ and R^{10} represents 10 $-S(O)_2R^{13}$ or $-C(O)OR^{17}$ may be prepared by cyclisation of a compound of formula XXIIIA,



15 wherein R^{10a} represents $-S(O)_2R^{13}$ or $-C(O)OR^{17}$ and m , R^4 , R^6 , R^{13} , R^{17} and L^2 are as hereinbefore defined, for example at between 0°C and reflux 20 temperature in the presence of a suitable base (e.g. sodium hydroxide), an appropriate solvent (e.g. dichloromethane, water, or a mixture thereof) and, if necessary, a phase transfer catalyst (such as tetrabutylammonium hydrogensulfate).


Compounds of formula VI may be prepared by standard techniques. For example compounds of formula VI in which:

(1) B represents $-(CH_2)_mO-$ may be prepared by coupling a compound of formula XIX, as hereinbefore defined, to a compound of formula XXIV,



wherein L^4 represents a suitable leaving group (e.g. Hal) and Hal, m, R^4 , A, D and L^2 are as hereinbefore defined;

(2) B represents $-C(O)N(R^{24})-$ may be prepared by coupling a compound of formula XXV,



wherein R^6 and R^{24} are as hereinbefore defined, to a compound of formula XXVI,




wherein L^4 , R^4 , A, D and L^2 are as hereinbefore defined;

in both cases, under conditions which are well known to those skilled in the art.

Compounds of formulae V and VI in which B represents $-(CH_2)_mS(O)-$ or $-(CH_2)_mS(O)_2-$ may be prepared by oxidation of the corresponding compounds of formulae V and VI (respectively) wherein B represents $-(CH_2)_mS-$, wherein m is as hereinbefore defined, in the presence of an appropriate amount of a suitable oxidising agent (e.g. *m*-chloroperbenzoic acid) and an appropriate organic solvent.

Compounds of formula VII may be prepared in a similar fashion to compounds of formula I (see, for example, process steps (a), (b) or (c)).


Alternatively, compounds of formula VII in which A represents C_2 alkylene may be prepared by reaction of a corresponding compound of formula IV, as hereinbefore defined with a compound of formula XXVII,



wherein R^6 and B are as hereinbefore defined, for example a room temperature in the presence of a suitable organic solvent (e.g. ethanol).

10

Compounds of formula IX may be prepared by reaction of a corresponding compound of formula XXVIIA,




wherein c, R¹, R², R³, R⁴, R^{5a}, R^{5b}, R⁶, X, A and B are as hereinbefore defined with a compound of formula XXVIIIB,



wherein R^y is C₁₋₄ alkyl or aryl (which two groups are optionally substituted with one or more substituents selected from C₁₋₄ alkyl or halo), for example at between -10 and 25°C in the presence of a suitable solvent (e.g. dichloromethane), followed by reaction with a suitable source of the azide ion (e.g. sodium azide) for example at between ambient and reflux temperature in the presence of an appropriate solvent (e.g. DMF) and a suitable base (e.g. NaHCO₃).

Compounds of formula IX may alternatively be prepared by reaction of a compound of formula IV as hereinbefore defined with a compound of formula XXVIIC,




wherein L², R⁴, R⁶, A, B and c are as hereinbefore defined, for example under analogous conditions to those described hereinbefore for preparation of compounds of formula I (process step (c)).

Compounds of formula XIII may be prepared by removing an optionally substituted benzyloxycarbonyl unit from (i.e. deprotecting) a corresponding compound of formula I in which D and R⁴ both represent H and B represents -N(R²⁴)C(O)O(CH₂)-, A represents A^a and A^a is as

hereinbefore defined under conditions which are well known to those skilled in the art.

Compounds of formula XVA may be prepared by reaction of a corresponding compound of formula VIII with hydroxylamine, for example at elevated temperature (e.g. at reflux) in the presence of a suitable organic solvent (e.g. methanol).

Compounds of formula XVI in which R^2 and R^3 both represent H may be prepared by reduction of a compound of formula XXVIII,




wherein R^{5a} and R^{5b} are as hereinbefore defined, under appropriate conditions (for example conditions such as those described in respect of the preparation of compounds of formula I (process step (e))).

Compounds of formula XVI in which R^2 represents OH and R^3 represents R^{3a} may be prepared by reaction of a corresponding compound of formula XXVIII as hereinbefore defined, with a compound of formula XVIIA as hereinbefore defined, under appropriate conditions (for example conditions such as those described for the production of compounds of formula II in which R^2 represents OH and R^3 represents R^{3a}).

Compounds of formula XVI in which R^2 and R^3 together represent

-O-(CH₂)₂-O-, -(CH₂)₃-, -(CH₂)₄- or -(CH₂)₅- may be prepared by reduction of a compound of formula XXVIIIA



wherein R^{2a} and R^{3a} together represent -O-(CH₂)₂-O-, -(CH₂)₃-, -(CH₂)₄- or


5 -(CH₂)₅- and R^{5a} and R^{5b} are as hereinbefore defined in the presence of a suitable reducing agent (e.g. LiAlH₄) under conditions that are well known to those skilled in the art.

10 Compounds of formula XXVIIIA may be prepared in analogous fashion to corresponding compounds of formula I.


Compounds of formula XXVIIC may be prepared in analogous fashion to a compound of formula IX (i.e. from the corresponding alcohol including a -(CH₂)_cOH group).

15

Compounds of formulae VIII, XVII, XVIII and XXVIII may be prepared, advantageously, by reaction of a compound of formula XXIX,



wherein R^z represents H or $-C(O)XR^1$ and R^1 , R^{5a} , R^{5b} and X are as hereinbefore defined with (as appropriate) either (1) a compound of formula XXX,




5

or a protected derivative thereof, wherein R^4 , R^6 , A, B and D are as hereinbefore defined, or (2) NH_3 (or a protected (e.g. benzyl) derivative thereof), in all cases in the presence of a formaldehyde (i.e. an appropriate 10 source of formaldehyde, such as paraformaldehyde or formalin solution).

The formation of compounds of formulae VIII, XVII, XVIII and XXVIII may be carried out in this way for example at between room temperature and reflux (depending upon the concentration of the reactants) in the 15 presence of an appropriate solvent (e.g. ethanol or methanol) and, preferably, in the presence of an organic acid (e.g. a C_{1-6} carboxylic acid, especially acetic acid).

Compounds of formula XXVIIIA may be prepared in accordance with 20 techniques which are well known to those skilled in the art. For example, compounds of formula XXVIIIA in which R^{2a} and R^{3a} together represent $-(CH_2)_3-$, $-(CH_2)_4-$ or $-(CH_2)_5-$ and R^{5a} and R^{5b} represent H may be prepared by reaction of a compound of formula XXXI,



XXXI

wherein $R^{2a'}$ and $R^{3a'}$ together represent $-(CH_2)_3-$, $-(CH_2)_4-$ or $-(CH_2)_5-$, and X and R^1 are as hereinbefore defined with a mixture of phosphoric acid and sulfuric acid, for example at 120°C.

Compounds of formula XXX are well known in the literature or are readily available using known techniques. For example, compounds of formula XXX wherein D represents -OH, R^4 represents H and A represents CH_2 may be prepared by reaction of a compound of formula V in which R^4 represents H with ammonium hydroxide under conditions which are well known to those skilled in the art.

Compounds of formulae III, VIIIA, X, XI, XIA, XII, XIV, XV, XVB, XVIIIA, XIX, XX, XXI, XXII, XXIII, XXIIIA, XXIV, XXV, XXVI, XXVII, XXVIIIB, XXIX and XXXI, and derivatives thereof, are either commercially available, are known in the literature, or may be obtained either by analogy with the processes described herein, or by conventional synthetic procedures, in accordance with standard techniques, from readily available starting materials using appropriate reagents and reaction conditions.

Substituents on the aryl (e.g. phenyl), and (if appropriate) heterocyclic, group(s) in compounds defined herein may be converted to other

substituents using techniques well known to those skilled in the art. For example, nitrobenzene may be reduced to an aminobenzene, hydroxy may be converted to alkoxy, alkoxy may be hydrolysed to hydroxy etc.

5 The compounds of the invention may be isolated from their reaction mixtures using conventional techniques.

It will be appreciated by those skilled in the art that, in the processes described above, the functional groups of intermediate compounds may be, 10 or may need to be, protected by protecting groups.

Functional groups which it is desirable to protect include hydroxy, amino and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl and diarylalkylsilyl groups (e.g. *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl and alkylcarbonyloxy groups (e.g. methyl- and ethylcarbonyloxy groups). 15 Suitable protecting groups for amino include benzyl, *tert*-butyloxycarbonyl, 9-fluorenylmethoxycarbonyl or benzyloxycarbonyl. Suitable protecting groups for carboxylic acid include C₁₋₆ alkyl or benzyl esters.

20

The protection and deprotection of functional groups may take place before or after any of the reaction steps described hereinbefore.

Protecting groups may be removed in accordance with techniques which are 25 well known to those skilled in the art and as described hereinafter.

The use of protecting groups is fully described in "Protective Groups in Organic Chemistry", edited by J W F McOmie, Plenum Press (1973), and

"Protective Groups in Organic Synthesis", 2nd edition, T W Greene & P G M Wutz, Wiley-Interscience (1991).

Persons skilled in the art will appreciate that, in order to obtain compounds
5 of the invention in an alternative, and, on some occasions, more convenient,
manner, the individual process steps mentioned herein may be performed in
a different order, and/or the individual reactions may be performed at a
different stage in the overall route (i.e. substituents may be added to and/or
10 chemical transformations performed upon, different intermediates to those
associated hereinbefore with a particular reaction). This will depend *inter*
alia on factors such as the nature of other functional groups present in a
particular substrate, the availability of key intermediates and the protecting
group strategy (if any) to be adopted. Clearly, the type of chemistry
involved will influence the choice of reagent that is used in the said
15 synthetic steps, the need, and type, of protecting groups that are employed,
and the sequence for accomplishing the synthesis.

It will also be appreciated by those skilled in the art that, although certain
20 protected derivatives of compounds of formula I, which may be made prior
to a final deprotection stage, may not possess pharmacological activity as
such, they may be administered parenterally or orally and thereafter
metabolised in the body to form compounds of the invention which are
pharmacologically active. Such derivatives may therefore be described as
25 "prodrugs". Moreover, certain compounds of formula I may act as
prodrugs of other compounds of formula I.

All prodrugs of compounds of formula I are included within the scope of the
invention.

Some of the intermediates referred to hereinbefore are novel. According to a further aspect of the invention there is thus provided compounds of formulae II, VIII and XVII as hereinbefore defined, or protected derivatives of all of these compounds, provided that, in all cases, when R^{5a} and R^{5b} both represent H, then D does not represent H or OH. There is further provided a compound of formula IV as hereinbefore defined, or a protected derivative thereof, provided that when R^{5a} and R^{5b} both represent H, then at least one of R² and R³ represents OR⁷, OC(O)R⁸ or C₁₋₄ alkyl, which alkyl group is substituted and/or terminated with one or more nitro or cyano groups.

Medical and pharmaceutical use

The compounds of the invention are useful because they possess pharmacological activity. They are therefore indicated as pharmaceuticals.

Thus, according to a further aspect of the invention there is provided the compounds of the invention for use as pharmaceuticals.

In particular, the compounds of the invention exhibit myocardial electrophysiological activity, for example as demonstrated in the test described below.

The compounds of the invention are thus expected to be useful in both the prophylaxis and the treatment of arrhythmias, and in particular atrial and ventricular arrhythmias.

The compounds of the invention are thus indicated in the treatment or prophylaxis of cardiac diseases, or in indications related to cardiac diseases, in which arrhythmias are believed to play a major role, including ischaemic heart disease, sudden heart attack, myocardial infarction, heart failure, 5 cardiac surgery and thromboembolic events.

In the treatment of arrhythmias, compounds of the invention have been found to selectively delay cardiac repolarization, thus prolonging the QT interval, and, in particular, to exhibit class III activity. Although 10 compounds of the invention have been found to exhibit class III activity in particular, in the treatment of arrhythmias, their mode(s) of activity is/are not necessarily restricted to this class.

According to a further aspect of the invention, there is provided a method of 15 treatment of an arrhythmia which method comprises administration of a therapeutically effective amount of a compound of the invention to a person suffering from, or susceptible to, such a condition.

Pharmaceutical preparations

20

The compounds of the invention will normally be administered orally, subcutaneously, intravenously, intraarterially, transdermally, intranasally, by inhalation, or by any other parenteral route, in the form of pharmaceutical preparations comprising the active ingredient either as a free 25 base, a pharmaceutically acceptable ion exchanger or a non-toxic organic or inorganic acid addition salt, in a pharmaceutically acceptable dosage form.

Depending upon the disorder and patient to be treated, as well as the route of administration, the compositions may be administered at varying doses.

The compounds of the invention may also be combined with any other drugs
5 useful in the treatment of arrhythmias and/or other cardiovascular disorders.

According to a further aspect of the invention there is thus provided a pharmaceutical formulation including a compound of the invention in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

10

Suitable daily doses of the compounds of the invention in therapeutic treatment of humans are about 0.05 to 5.0 mg/kg body weight at parenteral administration.

15

The compounds of the invention have the advantage that they are effective against cardiac arrhythmias.

20

Compounds of the invention may also have the advantage that they may be more efficacious than, be less toxic than, have a broader range of activity (including exhibiting any combination of class I, class II, class III and/or class IV activity (especially class I, class II and/or class IV activity in addition to class III activity)) than, be more potent than, produce fewer side effects (including a lower incidence of proarrhythmias such as *torsades de pointes*) than, be more easily absorbed than, or that they may 25 have other useful pharmacological properties over, compounds known in the prior art.

Biological Tests

Test A

Primary Electrophysiological Effects In Anaesthetised Guinea Pigs

5 Guinea pigs weighing between 660 an 1100 g were used. The animals were housed for at least one week before the experiment and had free access to food and tap water during that period.

Anaesthesia was induced by an intraperitoneal injection of pentobarbital (40
10 to 50 mg/kg) and catheters were introduced into one carotid artery (for blood pressure recording and blood sampling) and into one jugular vein (for drug infusions). Needle electrodes were placed on the limbs for recording of ECGs (lead II). A thermistor was placed in the rectum and the animal was placed on a heating pad, set to a rectal temperature of between 37.5 and
15 38.5°C.

A tracheotomy was performed and the animal was artificially ventilated with room air by use of a small animal ventilator, set to keep blood gases within the normal range for the species. In order to reduce autonomic influences
20 both vagi were cut in the neck, and 0.5 mg/kg of propranolol was given intravenously, 15 minutes before the start of the experiment.

The left ventricular epicardium was exposed by a left-sided thoracotomy, and a custom-designed suction electrode for recording of the monophasic
25 action potential (MAP) was applied to the left ventricular free wall. The electrode was kept in position as long as an acceptable signal could be recorded, otherwise it was moved to a new position. A bipolar electrode for pacing was clipped to the left atrium. Pacing (2 ms duration, twice the

diastolic threshold) was performed with a custom-made constant current stimulator. The heart was paced at a frequency just above the normal sinus rate during 1 minute every fifth minute throughout the study.

5 The blood pressure, the MAP signal and the lead II ECG were recorded on a Mingograph ink-jet recorder (Siemens-Elema, Sweden). All signals were collected (sampling frequency 1000 Hz) on a PC during the last 10 seconds of each pacing sequence and the last 10 seconds of the following minute of sinus rhythm. The signals were processed using a custom-made program
10 developed for acquisition and analysis of physiological signals measured in experimental animals (see Axenborg and Hirsch, Comput. Methods Programs Biomed. **41**, 55 (1993)).

15 The test procedure consisted of taking two basal control recordings, 5 minutes apart, during both pacing and sinus rhythm. After the second control recording, the first dose of the test substance was infused in a volume of 0.2 mL into the jugular vein catheter for 30 seconds. Three minutes later, pacing was started and a new recording was made. Five minutes after the previous dose, the next dose of test substance was
20 administered. Six to ten consecutive doses were given during each experiment.

Data analysis

25 Of the numerous variables measured in this analysis, three were selected as the most important for comparison and selection of active compounds. The three variables selected were the MAP duration at 75 percent repolarization during pacing, the atrio-ventricular (AV) conduction time (defined as the interval between the atrial pace pulse and the start of the ventricular MAP)

during pacing, and the heart rate (defined as the RR interval during sinus rhythm). Systolic and diastolic blood pressure were measured in order to judge the haemodynamic status of the anaesthetised animal. Further, the ECG was checked for arrhythmias and/or morphological changes.

5

The mean of the two control recordings was set to zero and the effects recorded after consecutive doses of test substance were expressed as percentage changes from this value. By plotting these percentage values against the cumulative dose administered before each recording, it was 10 possible to construct dose-response curves. In this way, each experiment generated three dose-response curves, one for MAP duration, one for AV-conduction time and one for the sinus frequency (RR interval). A mean curve of all experiments performed with a test substance was calculated, and potency values were derived from the mean curve. All dose-response 15 curves in these experiments were constructed by linear connection of the data points obtained. The cumulative dose prolonging the MAP duration by 10% from the baseline was used as an index to assess the class III electrophysiological potency of the agent under investigation (D_{10}).

20 The invention is illustrated by way of the following examples.

Examples

General Experimental Procedures

25 Mass spectra were recorded on a Finnigan MAT TSQ 700 triple quadrupole mass spectrometer equipped with an electrospray interface (FAB-MS) and VG Platform II mass spectrometer equipped with an electrospray interface (LC-MS), a Hewlett Packard model 6890 gas chromatograph connected to a Hewlett-Packard model 5973A mass spectrometer *via* a Hewlett Packard

HP-5-MS GC column, or a Shimadzu QP-5000 GC/mass spectrometer (CI, methane). ^1H NMR and ^{13}C NMR measurements were performed on a BRUKER ACP 300 and Varian UNITY plus 400 and 500 spectrometers, operating at ^1H frequencies of 300, 400 and 500 MHz respectively, and at ^{13}C frequencies of 75.5, 100.6 and 125.7 MHz respectively. Alternatively, ^{13}C NMR measurements were performed on a BRUKER ACE 200 spectrometer at a frequency of 50.3 MHz.

Rotamers may or may not be denoted in spectra depending upon ease of interpretation of spectra. Unless otherwise stated, chemical shifts are given in ppm with the solvent as internal standard.

Example 1

Ethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-hydroxy-3,7-diaza-15 bicyclo[3.3.1]nonane-3-carboxylate; diastereoisomers 1

(i) 4-(2-Oxiranylmethoxy)benzonitrile

Epichlorohydrin (800 mL) and K_2CO_3 (414 g) were added to a stirred solution of *p*-cyanophenol (238 g) in 2.0 L of acetonitrile. The reaction mixture was brought to reflux under an inert atmosphere for 2 h before being filtered whilst still hot. The resulting filtrate was concentrated to give a clear oil. This was crystallized from di-*iso*-propyl ether to give the sub-title compound in a 75% yield.

25 (ii) 3-(4-Cyanophenoxy)-2-hydroxypropylamine

IPA (300 mL) was added to a stirred suspension of 4-(2-oxiranylmethoxy)benzonitrile (from step (i) above; 100 g; 571 mmol) in NH_3 (500 mL; conc.), and the reaction mixture was stirred at rt for

3 days. The precipitate was filtered off and the residue concentrated and recrystallized from MeCN to give the sub-title compound in a 46% yield.

5 (iii) Ethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxy-3,7-diaza-
bicyclo[3.3.1]nonane-3-carboxylate

Glacial acetic acid (0.30 g; 5.0 mmol) in methanol (5 mL), and then paraformaldehyde (0.33 g; 11.0 mmol), were added to a stirred methanolic (5 mL) suspension of 3-(4-cyanophenoxy)-2-hydroxypropylamine (from step (ii) above; 0.96 g; 5.0 mmol) under an inert atmosphere (N₂). The temperature was brought to 55°C and a solution of 1-ethoxycarbonyl-4-piperidone (0.86 g; 5.0 mmol) in MeOH (5 mL) was added and the reaction mixture stirred for 6 h. The solids were filtered off and the solution was concentrated. The solid residue was partitioned between water and diethyl ether. The aqueous phase was collected and the pH adjusted to 10 (4 M NaOH) and extracted with CH₂Cl₂. The combined organic layers were concentrated and purified using column chromatography (CH₂Cl₂:MeOH; 19:1) to give the sub-title compound in 30% yield.

20 ¹³C NMR in CDCl₃: δ 14.5, 48.0, 50.6, 57.3, 61.2, 62.2, 65.4, 70.3, 104.2, 115.3, 119.0, 133.9, 157.9, 161.9, 211.7.

25 (iv) Ethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-hydroxy-3,7-diaza-
bicyclo[3.3.1]nonane-3-carboxylate; diastereoisomers 1

Sodium borohydride (100 mg; 2.6 mmol) was added to a cooled (0°C), stirred solution of ethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (iii) above; 354 mg; 0.91 mmol) in MeOH (3 mL). The reaction mixture was then stirred at rt for 1 h. The solvent was evaporated and the residue

partitioned between CH_2Cl_2 and NaHCO_3 (aq.). The organic layer was separated, dried, concentrated and subjected to column chromatography (hexane:EtOAc:MeOH; 35:60:5) to give two separable diastereoisomeric pairs. The title compound refers to the less polar diastereoisomers and was isolated in 58% yield.

^{13}C NMR in CDCl_3 : δ 15.0, 37.0, 48.9, 54.2, 61.5, 63.3, 66.1, 69.2, 72.1, 84.0, 104.5, 116.4, 119.6, 134.7, 161.9, 163.4.

10 Example 2

Ethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-hydroxy-3,7-diaza-bicyclo[3.3.1]nonane-3-carboxylate; diastereoisomers 2

The title compound was isolated in 24% yield as the more polar diastereoisomers from Example 1 above.

15

Example 3

tert-Butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-hydroxy-3,7-diaza-bicyclo[3.3.1]nonane-3-carboxylate; diastereoisomers 1

20 (i) tert-Butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxy-3,7-diaza-bicyclo[3.3.1]nonane-3-carboxylate

The sub-title compound was prepared according to the procedure described in Example 1(iii) above using 1-*tert*-butoxycarbonyl-4-piperidone in place of 1-ethoxycarbonyl-4-piperidone.

25

CI-MS (methane): m/z = 416 (MH^+).

(ii) tert-Butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate; diastereoisomers 1

The sub-title compound was prepared according to the procedure described in Example 1(iv) above, using *tert*-butyl 5 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxy-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate (from step (i) above) in place of ethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxy-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate. Spectral data was in agreement with data obtained from diastereoisomers 2 (described in Example 4). The title compound 10 refers to the less polar diastereoisomers.

Example 4

tert-Butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate; diastereoisomers 2

15 The title compound was isolated as the more polar diastereoisomers from Example 3 above.

^{13}C NMR in CDCl_3 : δ 28.6, 35.5, 47.4, 53.5, 61.4, 65.1, 69.2, 70.7, 79.9, 103.9, 115.3, 119.2, 133.9, 156.0, 162.2.

20

Example 5

tert-Butyl 7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-hydroxy-9-methyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

25 (i) 3,7-Dibenzyl-3,7-diazabicyclo[3.3.1]nonane-9-one

The sub-title compound was prepared according to the procedure described in *J. Org. Chem.*, **41**(9), 1976, pp. 1593-1597.

(ii) 3,7-Dibenzyl-9-hydroxy-9-methyl-3,7-diazabicyclo[3.3.1]nonane

A solution of 3,7-dibenzyl-3,7-diazabicyclo[3.3.1]nonane-9-one (from step (i) above; 2.05 g; 6.4 mmol) in diethyl ether (15 mL) was added to a stirred solution of methyl magnesium chloride (12.8 mmol) in diethyl ether (8 mL) over 80 minutes. The reaction mixture was subsequently stirred for 20 minutes and then quenched with HCl (1 M). The aqueous layer was separated, concentrated and partitioned between EtOAc and NaOH (2 M). The organic layer was separated and subsequently treated with ion exchange resin (Amberlyst IRA 400), the solvent removed and the residue subjected to column chromatography (hexane:EtOAc; 1:1 with NH₃ sat. MeOH; gradient 0-32%) to give the sub-title compound as a diastereoisomeric mixture in a 60% yield.

15 (iii) tert-Butyl 7-benzyl-9-hydroxy-9-methyl-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

A solution of 3,7-dibenzyl-9-hydroxy-9-methyl-3,7-diazabicyclo[3.3.1]-nonane (from step (ii) above, 1.0 g, 4.0 mmol) and di-*tert*-butyl dicarbonate (0.98 g, 4.25 mmol) in EtOH (50 mL) was hydrogenated over Pd/C for 20 minutes, filtered through a pad of Celite® and concentrated. Purification by column chromatography gave the sub-title compound in a 20 40% yield.

25 (iv) tert-Butyl 9-hydroxy-9-methyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

A solution of *tert*-butyl 7-benzyl-9-hydroxy-9-methyl-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate (from step (iii) above; 450 mg, 1.3 mmol) in aqueous ethanol (50 mL of 95%) was hydrogenated over 5% Pd/C at 1 atm until tlc indicated that the reaction was complete. The catalyst was removed by filtration through a pad of Celite®, and the filtrate

concentrated under reduced pressure to give the sub-title compound in quantitative yield.

(v) 4-[(2S)-Oxiranylmethoxy]benzonitrile

5 The sub-title compound was prepared in 90% yield according to the procedure described in Example 1(i) above, but using (*R*)-(-)-epichlorohydrin.

¹³C NMR in CDCl₃: δ 44.4, 49.7, 69.0, 104.6, 115.3, 119.0, 134.0, 161.6.

10

(vi) tert-Butyl 7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-hydroxy-9-methyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

4-[(2S)-Oxiranylmethoxy]benzonitrile (from step (v) above, 247 mg, 1.4 mmol) was added to a stirred solution of *tert*-butyl 9-hydroxy-9-methyl-15 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (iv) above, 328 mg, 1.28 mmol) in acetonitrile:water (4:1). The reaction was heated to 60°C for 12 h, after which stirring was continued at rt for a further 48 h. The reaction mixture was concentrated, dissolved in CH₂Cl₂, dried (MgSO₄) and then concentrated again. The residue was purified using 20 column chromatography to give the title compound in 44% yield.

¹³C NMR in CDCl₃: δ 14.10, 21.21, 21.79, 22.81, 25.95, 26.05, 28.44, 28.86, 31.75, 39.62, 39.99, 40.13, 40.31, 43.99, 46.45, 47.65, 52.21, 54.09, 55.71, 57.82, 60.02, 60.32, 60.55, 65.24, 67.95, 68.42, 68.65, 25 70.54, 79.43, 79.74, 103.82, 108.03, 115.30, 119.11, 126.22, 129.47, 133.81, 133.92, 139.48, 143.11, 156.05, 156.12, 156.19, 156.33, 162.09

Example 6*tert*-Butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-benzoyloxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate5 (i) *tert*-Butyl 7-[3-(4-cyanophenoxy)-2-(*tert*-butyldimethylsilyloxypropyl)]-9-oxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

A mixture of *tert*-butyldimethylchlorosilane (5.39 g, 35.7 mmol), *tert*-butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from Example 3(i) above; 13.5 g; 32.5 mmol) and imidazole (4.86 g; 71.4 mmol) in DMF was stirred for 20 h at rt. The mixture was diluted with CH₂Cl₂ (200 mL), then washed with water (2 x 100 mL) and saturated brine (2 x 100 mL). The organic layer was separated, dried (Na₂SO₄) and then concentrated to give a yellow oil. This was purified by column chromatography (EtOAc) to give 15 the sub-title compound in 77% yield.

15 (ii) *tert*-Butyl 7-[3-(4-cyanophenoxy)-2-(*tert*-butyldimethylsilyloxypropyl)]-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Sodium borohydride (2.66 g; 70.2 mmol) was added in portions to a 20 cooled (0°C), stirred solution of *tert*-butyl 7-[3-(4-cyanophenoxy)-2-(*tert*-butyldimethylsilyloxypropyl)]-9-oxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (i) above; 13.3 g; 25.1 mmol) in methanol (75 mL). The mixture was stirred for 3 h at rt before the solvent was 25 evaporated under reduced pressure. The oily residue was diluted with 100 mL of saturated aqueous NaHCO₃, and then extracted with CH₂Cl₂ (3 x 100 mL). The combined organic layers were dried (Na₂SO₄) and then concentrated to give a white foam. This was purified by column chromatography (EtAc:hexane; 1:1) to give the sub-title compound in 50% yield.

CI-MS (methane): m/z = 532 (MH⁺).

¹³C NMR in CDCl₃: δ -4.7, -4.5, 25.7, 28.6, 35.4, 35.6, 41.7, 42.6, 47.7, 48.6, 53.0, 53.8, 60.3, 61.5, 61.9, 68.9, 69.9, 71.5, 78.9, 79.5, 103.6, 103.9, 115.6, 119.3, 133.9, 155.2, 162.3

5

(iii) tert-Butyl 7-[3-(4-cyanophenoxy)-2-(tert-butyldimethylsilyloxypropyl)]-9-benzyloxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Benzoic acid (517 mg; 4.23 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (811 mg; 4.23 mmol) and

10 4-dimethylaminopyridine (35 mg; 0.282 mmol) were added to *tert*-butyl 7-[3-(4-cyanophenoxy)-2-(*tert*-butyldimethylsilyloxypropyl)]-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (ii) above; 1.5 g; 2.82 mmol) in 15 mL of THF. The mixture was stirred for 24 h at rt before being diluted with ethyl acetate. The resulting solution was washed 15 with water (2 x 50 mL) and brine (2 x 50 mL). The organic layer was then separated, dried (Na₂SO₄) and then concentrated to give an oil. This was purified by column chromatography (EtOAc:hexane; 1:5) to give the sub-title compound as a mixture of separable diastereoisomers in a total of 44% yield.

20 (a) Diastereoisomers 1 (the less polar compound)

¹³C NMR in CDCl₃: δ -4.8, -4.6, 18.0, 25.7, 28.6, 33.1, 42.4, 43.3, 58.3, 58.8, 59.5, 59.9, 61.2, 61.5, 69.3, 69.8, 71.1, 71.5, 72.0, 79.1, 103.6, 115.6, 119.2, 128.4, 129.9, 133.1, 133.8, 154.9, 162.4, 165.4.

CI-MS (methane): m/z = 636 (MH⁺).

25 (b) Diastereoisomers 2 (the more polar compound)

CI-MS (methane): m/z = 636 (MH⁺).

¹³C NMR in CDCl₃: δ -4.7, -4.5, 18.0, 25.7, 28.5, 33.5, 47.6, 48.6, 53.2, 54.0, 54.5, 55.0, 62.4, 69.3, 69.7, 71.3, 71.6, 79.2, 103.6, 115.6, 119.2, 128.4, 129.5, 130.2, 133.1, 133.9, 154.7, 162.4, 165.4.

(iv) tert-Butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-benzyloxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate; Diastereoisomers 1

Diastereoisomers 1 from step (iii) above (200 mg; 0.315 mmol) was mixed with tetrabutylammonium fluoride (0.47 mL; 0.47 mmol; 1.0 M in THF) in THF (2.0 mL), and stirred for 2 h at rt. The mixture was partitioned with ethyl acetate (3 x 20 mL) and water (20 mL), the organic layer separated, dried over Na_2SO_4 and then concentrated. The resulting oil was purified using column chromatography (hexane:EtOAc; 1:1) to give the sub-title compound in 79% yield.

10

CI-MS (methane) $m/z = 522$ (MH^+)

^{13}C NMR in CDCl_3 : δ 28.6, 32.9, 33.3, 42.3, 43.5, 55.8, 59.3, 60.2, 60.7, 65.5, 70.5, 72.3, 79.9, 104.0, 115.3, 119.0, 128.4, 129.5, 129.9, 133.2, 133.8, 156.0, 162.0, 165.4.

15

(v) tert-Butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-benzyloxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate; Diastereoisomers 2

The sub-title compound was prepared according to the procedure of step (iv) above, using Diastereoisomers 2 from step (iii) above, in 75% yield.

20

CI-MS (methane) $m/z = 522$ (MH^+).

^{13}C NMR in CDCl_3 : δ 28.6, 33.1, 33.6, 47.3, 48.4, 49.0, 50.7, 54.4, 61.6, 65.1, 65.9, 70.7, 72.2, 80.0, 104.0, 115.3, 119.0, 128.4, 129.4, 130.0, 133.1, 133.8, 155.9, 162.1, 165.3.

25

Example 7

tert-Butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-propionyloxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate; diastereoisomers 1

5 (i) tert-Butyl 7-[3-(4-cyanophenoxy)-2-(*tert*-butyldimethylsilyloxypropyl)]-9-propionyloxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The sub-title compound was prepared in a 69% yield according to the procedure described in Example 6(iii) above, using propionic acid in place of benzoic acid.

10

CI-MS (methane): m/z = 588 (MH⁺).

(ii) tert-Butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-propionyloxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate; diastereoisomers 1

15 The title compound was prepared in 64% yield according to the procedure of Example 6(iv) above, using *tert*-butyl 7-[3-(4-cyanophenoxy)-2-(*tert*-butyldimethylsilyloxypropyl)]-9-propionyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (i) above).

CI-MS (methane) m/z = 474 (MH⁺).

20

Example 8

tert-Butyl 7-[3-(4-cyanoanilino)propyl]-9-hydroxy-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

25 (i) tert-Butyl 7-benzyl-9-oxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Paraformaldehyde (4.00 g; 127 mmol) was added to a solution of benzylamine (13.7 g; 126 mmol) in ethanol (190 mL). The solution was heated to 60°C and a solution of acetic acid (15.2 g; 252 mmol) in ethanol (160 mL) was added over 2 hours. After additional stirring for 1 hour,

the solution was cooled to room temperature. This solution was added (over 2 hours) to a mixture of 1-*tert*-butoxycarbonyl-4-piperidone (25.5 g; 127 mmol) and paraformaldehyde (4.80 g; 152 mmol) in ethanol (270 mL) which had been heated to 60°C. After reflux overnight, the solution was 5 cooled to room temperature. The ethanol was removed by evaporation. Extractive work-up was performed in toluene:water and the material was filtered through silica in a toluene:ethyl acetate system. Evaporation of the eluant gave a solid material (37.4 g). The purity was 90 area% (HPLC) and the was yield 60%. By performing a crystallisation in IPA, a 10 compound with a purity of 98 area% (HPLC) and a yield of 70% was obtained.

EI-MS: m/z = 330 (M⁺).

¹³C NMR (CDCl₃): δ 28.72, 47.71, 49.91, 50.60, 58.83, 59.16, 61.96, 15 80.18, 127.37; 128.45, 128.89. 137.57, 154.89, 213.66.

(ii) *tert*-Butyl 7-benzyl-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Sodium borohydride (2.77 g; 73.2 mmol) was added to a cooled (0°C), 20 stirred solution of *tert*-butyl 7-benzyl-9-oxy-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate (from step (i) above; 8.01 g; 24.4 mmol) in methanol (125 mL). Once addition was complete, the reaction was stirred at rt overnight. The solvent was then evaporated and the residue re-dissolved in toluene. This solution was washed with water and brine, and 25 the resulting organic layer then separated, dried (Na₂SO₄) and concentrated to give the sub-title compound in quantitative yield.

(iii) tert-Butyl 9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The sub-title compound was prepared in quantitative yield according to the procedure of Example 5(iv) above, using *tert*-butyl 7-benzyl-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate in place of *tert*-butyl 7-benzyl-9-hydroxy-9-methyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate.

(iv) (4-Cyanoanilino)propan-3-ol

A mixture of 4-fluorobenzonitrile (1.0 g, 8.26 mmol) and 3-aminopropanol (4.54 g, 58.7 mmol) was refluxed under an inert atmosphere (N₂) for 15 h. Water (500 mL) and diethyl ether (500 mL) were then added, and the resulting organic layer separated, dried (Na₂SO₄) and concentrated. The residue was purified by column chromatography (heptane:EtOAc; 1:3) to give the sub-title compound in 84% yield.

15 (v) (4-Cyanoanilino)propyl-3-methanesulfonate

Methanesulfonyl chloride (0.33 g, 2.9 mmol) was added to a cooled (0°C), stirred solution of (4-cyanoanilino)propan-3-ol (from step (iv) above; 0.48 g, 2.76 mmol) and triethylamine (0.56 g, 5.54 mmol) in dichloromethane (35 mL). After addition was complete, stirring was continued at rt until all of the starting material had been consumed (as indicated by tlc). NaHCO₃ solution was added, and the resulting organic layer was separated, dried (Na₂SO₄) and concentrated to give the sub-title compound in quantitative yield.

25 (vi) tert-Butyl 7-[3-(4-cyanoanilino)propyl]-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

tert-Butyl 9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (iii) above; 0.84 g; 3.48 mmol) was added to a stirred suspension of anhydrous potassium carbonate (0.67 g; 4.8 mmol) and

(4-cyanoanilino)propyl-3-methanesulfonate (from step (v) above; 0.89 g; 3.48 mmol) in MeCN (5 mL) under an inert atmosphere (N_2). The reaction mixture was stirred for 10 h at rt, before the solvent was removed under reduced pressure. The residue was partitioned between CH_2Cl_2 and 5 $NaHCO_3$ (aq.), and then the organic layer separated, dried (Na_2SO_4) and concentrated. Purification by column chromatography gave the title compound in 41 % yield.

FAB-MS: $m/z = 401.08 (MH^+)$

10 ^{13}C NMR in $CDCl_3$: δ 25.9, 28.5, 35.5, 41.2, 47.6, 48.6, 51.8, 52.8, 56.1, 70.0, 79.5, 97.8, 111.9, 120.6, 133.7, 151.4, 155.3

Example 9

iso-Propyl 7-[2-amino-2-(4-cyanophenyl)ethyl]-3,7-diazabicyclo[3.3.1]-
15 nonane-3-carboxylate

(i) 3,7-Dibenzyl-3,7-diazabicyclo[3.3.1]nonane

The sub-title compound was prepared according to the procedure described in *J. Org. Chem.*, **41** (1976) 1593-1597, using 3,7-dibenzyl-3,7-20 diazabicyclo[3.3.1]nonane-9-one (Example 5(i) above) in place of N-benzyl-N'-methylbispidone.

(ii) 3-Benzyl-3,7-diazabicyclo[3.3.1]nonane

The sub-title compound was prepared in quantitative yield according to the procedure of Example 5(iv) above, using 3,7-dibenzyl-3,7-diazabicyclo[3.3.1]nonane (from step (i) above) in place of *tert*-butyl 7-benzyl-9-hydroxy-9-methyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate.

¹³C NMR in CDCl₃: δ 30.1, 33.4, 36.0, 52.5, 59.6, 64.3, 126.9, 128.3, 128.7, 138.8.

(iii) *iso*-Propyl 7-benzyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

5 *iso*-Propylchloroformate (55 mmol) and concentrated NaOH (6.0 mL; 10 M) were added, along with 10 mL of water, to a solution of 3-benzyl-3,7-diazabicyclo[3.3.1]nonane (from step (ii) above; 10.8 g; 50 mmol) in CH₂Cl₂ (50 mL). The reaction mixture was stirred for 3 h and the phases separated. The organic phase was washed with H₂O and brine, dried and 10 concentrated to give the sub-title compound in 95% yield.

(iv) *iso*-Propyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The sub-title compound was prepared in quantitative yield according to the procedure of Example 5(iv) above, using *iso*-propyl 7-benzyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (iii) above) in place of *tert*-butyl 7-benzyl-9-hydroxy-9-methyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate.

FAB-MS: m/z = 213.2 (MH⁺).

20 ¹³C NMR in CD₃CN: δ 22.53, 29.34, 32.23, 49.46, 52.40, 68.67, 156.24.

(v) *iso*-Propyl 7-[2-(4-cyanophenyl)-2-hydroxyethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

4-Cyanophenacyl bromide (225 mg; 1 mmol) was added to a stirred 25 solution of *iso*-propyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (iv) above; 212 mg; 1 mmol) in MeCN (2 mL). After stirring for 15 min at 0°C, NaBH₄ (40 mg; 1 mmol) was added, and the reaction was allowed to warm to rt over 45 minutes. The reaction mixture was concentrated, dissolved in CH₂Cl₂ and washed with NaHCO₃ (aq.) and

brine. The organic layer was separated, dried and concentrated to give an oil which was purified using column chromatography (hexane:EtOAc:IPA; 50:49:1) to give the sub-title compound in 35% yield.

5 (vi) *iso*-Propyl 7-[2-(4-cyanophenyl)-2-chloroethyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

Methanesulfonyl chloride (2.15 mL; 27 mmol) was added to a cooled (-10°C), stirred solution of *iso*-propyl 7-[2-(4-cyanophenyl)-2-hydroxyethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (v) above; 10 7.35 g; 21 mmol) in CH₂Cl₂ (30 mL). After addition, the reaction mixture was stirred at rt for 3 h. The solvent was evaporated to give the sub-title compound in a quantitative yield.

15 (vii) *iso*-Propyl 7-[2-azido-2-(4-cyanophenyl)ethyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

Sodium azide (6.5 g; 100 mmol) was added to a solution of 7-[2-(4-cyanophenyl)-2-chloroethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (vi) above; 7.73 g; 21 mmol) in DMF (75 mL). The resulting suspension was stirred for 12 h at rt. The reaction mixture was 20 partitioned between CH₂Cl₂ and NaHCO₃ (aq.), the organic layer separated, dried and then concentrated to give the sub-title compound in 95% yield.

25 (viii) *iso*-Propyl 7-[2-amino-2-(4-cyanophenyl)ethyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

A solution of *iso*-propyl 7-[2-azido-2-(4-cyanophenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (vii) above; 7.51 g; 19.5 mmol) in aqueous ethanol (85%) was hydrogenated over 5% Pd/C at 1 atm until tlc indicated that the reaction was complete. The catalyst was

removed by filtration through a pad of Celite®, and the filtrate concentrated under reduced pressure to give the title compound in 98% yield.

5 FAB-MS: m/z = 357.0 (MH⁺)

¹³C NMR in CDCl₃: δ 22.63, 30.05, 30.30, 32.50, 48.88, 49.26, 52.70, 57.53, 61.32, 68.54, 68.67, 110.97, 119.87, 128.68, 132.90, 152.56, 156.43

10 Example 10

iso-Propyl 7-[2-carbamoylamino-2-(4-cyanophenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

A solution of tetrahydro-2-pyranyl isocyanate (382 mg, 3.0 mmol) in benzene (10 mL) was added to a stirred solution of *iso*-propyl 7-[2-amino-

15 2-(4-cyanophenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (see Example 9 above; 1.07 g; 3.0 mmol) in benzene (35 mL). The reaction mixture was stirred for 2 h at rt, after which the solvent was evaporated and the residue re-dissolved in a mixture of MeOH (27 mL) and dilute HCl (4.5 mL; 0.1 M). The resulting solution was refluxed for 3 h, before 20 the acid was neutralized (NaHCO₃) and the MeOH removed by evaporation to give a precipitate which was collected and recrystallized from IPA to give the title compound in 67% yield.

FAB-MS: m/z = 399.7 (MH⁺)

25 ¹³C NMR in CDCl₃: δ 22.35, 22.69, 28.67, 29.12, 32.42, 48.11, 49.15, 51.76, 55.83, 59.13, 63.54, 68.88, 110.49, 119.11, 126.62, 132.29, 149.14, 156.62, 159.76

Example 11*iso*-Propyl 7-[2-carbamoylcarboxamido-2-(4-cyanophenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

iso-Propyl 7-[2-amino-2-(4-cyanophenyl)ethyl]-3,7-diazabicyclo[3.3.1]-

5 nonane-3-carboxylate (see Example 9 above; 0.36 g; 1.0 mmol) and 1-hydroxybenzotriazole hydrate (0.28 g; 2 mmol) were added to a stirred solution of oxalic acid diamide (0.1 g; 1.1 mmol) in DMF (8 mL). Triethylamine was added until the pH reached 7-8, after which the reaction mixture was cooled to 0°C whilst 1-(3-dimethylaminopropyl)-3-
10 ethylcarbodiimide hydrochloride (0.23 g; 1.2 mmol) was added. The reaction mixture was then stirred at rt for 10 h, after which water (15 mL) was added and the DMF evaporated. The residue was partitioned between diethyl ether and NaHCO₃ (aq.), the organic layer separated, washed with water, dried and then concentrated. The resulting residue was
15 recrystallized from MeOH and di-*iso*-propyl ether to give the title compound in 45% yield.

ESI-MS: m/z = 428.3 (MH⁺)

¹³C NMR in CDCl₃: δ 22.34, 28.62, 29.58, 29.89, 48.04, 51.10, 52.03,
20 58.67, 59.48, 59.66, 63.65, 68.03, 111.38, 118.53, 127.25, 132.41,
145.77, 155.71, 159.24, 161.43

Example 12*iso*-Propyl 7-[2-(4-cyanophenyl)-2-formamidoethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

25 Ethyl formate (0.5 mL) was added to a stirred solution of *iso*-propyl 7-[2-amino-2-(4-cyanophenyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from Example 9(viii) above; 0.71 g; 2.0 mmol), and the reaction mixture was refluxed for 5 h. The solvent was evaporated and

the residue partitioned between diethyl ether and NaOH (2 M). The organic layer was separated, washed with water, dried and then concentrated. The resulting residue was then recrystallized from MeOH and di-*iso*-propyl ether to give the title compound in 40% yield.

5

FAB-MS: m/z = 384.9 (MH⁺)

¹³C NMR in CDCl₃: δ 22.44, 22.78, 28.68, 29.13, 32.39, 48.13, 49.17, 50.54, 56.00, 59.16, 63.07, 68.39, 110.97, 118.81, 126.68, 132.43, 147.02, 156.76, 163.01

10

Example 13

tert-Butyl 7-[2-amino-3-(4-cyanophenoxy)propyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

15

(i) Benzyl 3-(4-cyanophenoxy)-2-hydroxypropylcarbamate

4-(3-Amino-2-hydroxypropoxy)benzonitrile (see Example 1(ii) above; 30.0 g; 0.156 mol) and triethylamine (23.7 g; 0.234 mol) was dissolved in 150 mL of CHCl₃, and cooled to 0°C. N-(Benzylloxycarbonyloxy)succinimide (42.9 g; 0.172 mol), dissolved in 150 mL of CHCl₃, was added dropwise. The mixture was stirred at rt overnight. The solvent was evaporated, the residue was dissolved in DCM and washed with H₂O (2 x 250 mL) and brine (250 mL), dried, and evaporated to give 51 g (100%) of the sub-title compound.

25

(ii) 2-{[(Benzyl)carbonyl]amino}-1-[(4-cyanophenoxy)methyl]ethyl methanesulfonate

Benzyl 3-(4-cyanophenoxy)-2-hydroxypropylcarbamate (2 g; 6.1 mmol; from step (i) above) and a catalytic amount (10 mol%) of DMAP was mixed in 6 mL of dry pyridine. The mixture was cooled to 0°C, and

methanesulfonyl chloride (0.52 mL; 1.1 eq.) was added dropwise at 0°C. The mixture was allowed to reach room temperature for 3 h. The pyridine was evaporated. Ethyl acetate was added, the solution was washed with water, and the organic layer was separated, dried and evaporated to give 2.3 g (93%) of the sub-title compound.

5 (iii) Benzyl 2-[(4-cyanophenoxy)methyl]-1-aziridinecarboxylate

2-{[(Benzyl)carbonyl]amino}-1-[(4-cyanophenoxy)methyl]ethyl methanesulfonate (47.7 mg; 0.12 mol; from step (ii) above), 10 tetrabutylammonium hydrogensulfate (4.81 g; 0.014 mol) and 290 mL of DCM were mixed and cooled to 0°C. 97 mL of 50% NaOH was added and the mixture was stirred vigorously for 50 minutes. 500 mL of water and 500 mL of ether were added. The organic phase was separated, washed with water, dried (Na_2SO_4) and evaporated. Purification by 15 chromatography on silica (DCM) gave 33.13 g (89%) of the sub-title compound.

20 (iv) tert-Butyl 7-benzyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Di-*tert*-butyl dicarbonate was added slowly to a solution of 3-benzyl-3,7- 25 diazabicyclo[3.3.1]nonane (see Example 9(ii) above; 60 g; 277 mmol) in THF (600 mL). The reaction was stirred at rt until all of the starting material had been consumed (as indicated by tlc). The solvent was then removed under reduced pressure to give a quantitative yield of the sub-title compound.

25

(v) tert-Butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The sub-title compound was prepared in quantitative yield according to the procedure of Example 5(iv) above, using *tert*-butyl 7-benzyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (iv) above) in place of

5 *tert*-butyl 7-benzyl-9-hydroxy-9-methyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate.

10 ^{13}C NMR in CDCl_3 : δ 28.05, 28.29, 31.33, 48.35, 49.11, 51.53, 79.34,

15 155.16

(vi) *tert*-Butyl 7-[2-{[(benzyloxy)carbonyl]amino}-3-(4-cyanophenoxy)propyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

10 Benzyl 2-[(4-cyanophenoxy)methyl]-1-aziridinecarboxylate (1.0 g; 3.2 mmol; from step (iii) above) was mixed with *tert*-butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (v) above; 0.73g; 3.2 mmol) and 30 mL of *iso*-propanol, and stirred at 60°C for 5 h, and then at rt overnight. The solvent was evaporated and the crude material was purified on silica (DCM:5% MeOH) yielding 1.3 g (76%) of sub-title 15 compound.

(vii) *tert*-Butyl 7-[2-amino-3-(4-cyanophenoxy)propyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

20 *tert*-Butyl 7-[2-{[(benzyloxy)carbonyl]amino}-3-(4-cyanophenoxy)propyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (vi) above; 3 g; 5.6 mmol) was dissolved in ethanol (95%) and hydrogenated over 5% Pd/C at 1 atm., for 2 hours. The catalyst was removed by filtration through a pad of Celite®. The residue was evaporated, and purified by chromatography (ethyl acetate:10% MeOH). Yield: 2 g (91%).

25

^{13}C NMR in MeOD : δ 29.01, 30.43, 31.86, 59.57, 59.96, 61.63, 61.87, 62.71, 72.34, 80.93, 105.03, 116.85, 119.98, 135.25, 156.88, 163.85

(The (*R*)- and (*S*)- isomers were made from chiral 4-(2-oxiranylmethoxy)benzonitrile: 4-(2(*R*)-oxiranylmethoxy)benzonitrile provided the *S*-form of *tert*-butyl 7-[2-amino-3-(4-cyanophenoxy)propyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate, and 4-(2(*S*)-oxiranylmethoxy)benzonitrile provided the *R*-form.)

Example 14

tert-Butyl 7-[2-amino-3-(4-cyanophenoxy)propyl]-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

10

(i) *tert*-Butyl 7-[2-[(benzyloxy)carbonyl]amino]-3-(4-cyanophenoxy)propyl]-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

tert-Butyl 9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (3.85

g; 15.9 mmol; see Example 8(iii) above) was mixed with benzyl 2-[(4-cyanophenoxy)methyl]-1-aziridinecarboxylate (4.44 g, 14.4 mmol; see Example 13(iii) above) in 100 mL of *iso*-propanol:H₂O (8:2). The mixture was stirred at 60°C for 24 h. The solvent was evaporated and the residue was purified by chromatography on silica (toluene:ethyl acetate:*iso*-propanol; 8:1:1). Yield 6.21 g (78%).

20

(ii) *tert*-Butyl 7-[2-amino-3-(4-cyanophenoxy)propyl]-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

tert-Butyl 7-[2-[(benzyloxy)carbonyl]amino]-3-(4-cyanophenoxy)propyl]-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (i)

25 above; 6.17 g; 11.2 mmol) was dissolved in ethanol (56 mL; 85%) and hydrogenated over Pd/C (5%). The resultant mixture was filtered, the solvent was evaporated and the crude product was purified by chromatography on silica (toluene:ethyl acetate:*iso*-propanol; 8:1:1) which gave 2.99 g (64%) of the title compound.

FAB-MS: m/z = 417.4 (MH⁺)

¹³C NMR in MeOD: δ 27.82, 35.77, 51.40, 51.94, 53.55, 53.91, 61.60, 68.11, 71.23, 79.81, 103.76, 115.55, 118.85, 133.98, 155.41, 162.59

5 Example 15

tert-Butyl 7-[3-(4-cyanoanilino)propyl]-9-hydroxy-1,5-dimethyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

(i) 3,7-Dibenzyl-1,5-dimethyl-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane

10 The sub-title compound was prepared according to the procedure described in *Chem. Heterocycl. Compd.*, **30** (1994) 353-357.

(ii) 3-Benzyl-1,5-dimethyl-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane

15 A solution of 3,7-dibenzyl-1,5-dimethyl-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane (from step (i) above; 2.71 g, 7.74 mmol) in aqueous ethanol (20 mL; 95%) was hydrogenated over 5% Pd/C at 1 atm. until tlc indicated that the reaction was complete. The catalyst was removed by filtration through a pad of Celite®, and the filtrate concentrated to give the sub-title compound in a quantitative yield.

20

(iii) tert-Butyl 7-benzyl-1,5-dimethyl-9-hydroxy-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

25 Di-*tert*-butyl dicarbonate was added slowly to a solution of 3-benzyl-1,5-dimethyl-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane (from step (ii) above; 0.68 g; 2.61 mmol) in THF (5 mL). The reaction was stirred at rt until all of the starting material had been consumed (as indicated by tlc). The solvent was removed under reduced pressure to give the sub-title compound in a 89% yield.

(iv) tert-Butyl 1,5-dimethyl-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The sub-title compound was prepared in quantitative yield according to the procedure described in step (ii) above, using *tert*-butyl 7-benzyl-1,5-dimethyl-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (iii) above) in place of 3,7-dibenzyl-1,5-dimethyl-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane.

(v) tert-Butyl 7-[3-(4-cyanoanilino)propyl]-9-hydroxy-1,5-dimethyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

tert-Butyl 1,5-dimethyl-9-hydroxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (iv) above; 1.05 g, 3.89 mmol) was dissolved in 10 mL of MeCN. Triethylamine (0.39 g, 3.89 mmol) and (4-cyanoanilino)propyl-3-methanesulfonate (see Example 8(v) above; 0.99 g, 3.89 mmol) were added. The reaction mixture was stirred for 72 h at 60°C, before the solvent was removed under reduced pressure. The residue was partitioned between CH₂Cl₂ and NaHCO₃ (aq.), and then the organic layer separated, dried (Na₂SO₄) and concentrated. Purification by column chromatography gave the title compound in a 4% yield.

20

FAB-MS: m/z = 429.0 (MH)⁺

¹H NMR in CDCl₃: δ 0.99 (s, 6H), 1.45 (s, 9H), 2.00-2.18 (m, 2H), 2.49-3.60 (m, 12 H), 3.61-3.88 (m, 2H), 3.90-4.08 (m, 1H), 6.54-6.66 (d, 2H), 7.38-7.46 (d, 2H)

25

Example 16

The compounds of the above Examples 1 to 15 were tested in Test A above and were all found to exhibit D₁₀ values of more than 6.0.

Abbreviations


AcOH =	acetic acid
aq. =	aqueous
5 atm. =	atmospheres
Bu =	butyl
DCM =	dichloromethane
DMAP =	4-dimethylaminopyridine
DMF =	dimethylformamide
10 EI =	electron ionisation
Et =	ethyl
EtOAc =	ethyl acetate
EtOH =	ethanol
ESI =	electron spray interface
15 FAB =	fast atom bombardment
h =	hours
IPA =	<i>iso</i> -propanol
LC =	liquid chromatography
HPLC =	high performance liquid chromatography
20 Me =	methyl
MeCN =	acetonitrile
MeOH =	methanol
min. =	minutes
MS =	mass spectroscopy
25 NADPH =	nicotinamide adenine dinucleotide phosphate, reduced form
NMR =	nuclear magnetic resonance
Pd/C =	palladium on carbon
rt. =	room temperature

sat. =	saturated
THF =	tetrahydrofuran
tlc =	thin layer chromatography

5 Prefixes *n*, *s*, *i* and *t* have their usual meanings: normal, iso, secondary and tertiary.

Claims

1. A compound of formula I,



wherein

R¹ represents C₁₋₁₂ alkyl, -(CH₂)_a-aryl, or -(CH₂)_a-Het¹ (all of which are 10 optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, halo, cyano, nitro, C₁₋₄ alkyl and/or C₁₋₄ alkoxy);

a represents 0, 1, 2, 3, or 4;

Het¹ represents a five to ten-membered heterocyclic ring containing one or 15 more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

X represents O or S;

R^{5a} and R^{5b} independently represent H or C_{1-3} alkyl;

R^2 and R^3 independently represent H, C_{1-4} alkyl (optionally substituted and/or terminated with one or more nitro or cyano groups), OR^7 ,

5 $N(R^{7a})R^{7b}$, $OC(O)R^8$ or together form $-O-(CH_2)_2-O-$, $-(CH_2)_3-$, $-(CH_2)_4-$ or $-(CH_2)_5-$;

R^7 and R^8 independently represent H, C_{1-6} alkyl or $-(CH_2)_b$ -aryl (which latter two groups are optionally substituted and/or terminated by one or more substituents selected from -OH, halo, cyano, nitro, C_{1-4} alkyl and/or

10 C_{1-4} alkoxy);

R^{7a} and R^{7b} independently represent H or C_{1-6} alkyl;

b represents 0, 1, 2, 3 or 4;

R^4 represents H or C_{1-6} alkyl;

15

D represents H, C_{1-4} alkyl, -OH, or $-(CH_2)_cN(R^{10})(R^{11})$;

c represents 0, 1, 2, 3 or 4;

R^{10} represents H, C_{1-6} alkyl, $-(CH_2)_d$ -aryl, $-C(NH)NH_2$, $-S(O)_2R^{13}$, $-[C(O)]_eN(R^{14})(R^{15})$, $-C(O)R^{16}$ or $-C(O)OR^{17}$;

20 e represents 1 or 2;

R^{11} represents H, C_{1-6} alkyl, $-C(O)R^{18}$ or $-(CH_2)_f$ -aryl (which latter group is optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

25

R^{14} , R^{15} , R^{16} , R^{17} and R^{18} independently represent H, C_{1-6} alkyl, Het^2 or $-(CH_2)_g$ -aryl (which latter three groups are optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

R^{13} represents C_{1-6} alkyl, aryl or $-(CH_2)_h$ -aryl (all of which are all optionally substituted and/or terminated (as appropriate) by one or more substituents chosen from halo, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

d, f, g and h independently represent 0, 1, 2, 3 or 4;

5 Het² represents a five to ten-membered heterocyclic ring containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;

R^6 represents one or more optional substituents selected from -OH, cyano,

10 halo, amino, nitro, C_{1-6} alkyl (optionally terminated by $-N(H)C(O)OR^{18a}$), C_{1-6} alkoxy, $-C(O)N(H)R^{19}$, $-NHC(O)N(H)R^{20}$, $-N(H)S(O)_2R^{21}$ and/or $-OS(O)_2R^{22}$;

R^{19} and R^{20} independently represent H or C_{1-6} alkyl;

R^{18a} , R^{21} and R^{22} independently represent C_{1-6} alkyl;

15

A represents a single bond, C_{1-6} alkylene, $-N(R^{23})(CH_2)_j-$, $-O(CH_2)_j-$ or $-(CH_2)_jC(H)(OR^{23})(CH_2)_k-$ (in which latter three groups, the $-(CH_2)_j-$ group is attached to the bispidine nitrogen atom, and which latter four groups are all optionally substituted by one or more OH groups);

20 B represents a single bond, C_{1-4} alkylene, $-(CH_2)_mN(R^{24})-$, $-(CH_2)_mS(O)_n-$, $-(CH_2)_mO-$ (in which three latter groups, the $-(CH_2)_m-$ group is attached to the carbon atom bearing D and R^4), $-C(O)N(R^{24})-$ (in which latter group, the $-C(O)-$ group is attached to the carbon atom bearing D and R^4), $-N(R^{24})C(O)O(CH_2)_m-$ or $-N(R^{24})(CH_2)_m-$ (in which latter two groups, the $N(R^{24})$ group is attached to the carbon atom bearing D and R^4);

25 j, k and m independently represent 0, 1, 2, 3 or 4;

n represents 0, 1 or 2;

R^{23} represents H, C_{1-6} alkyl or $C(O)R^{25}$;

R^{24} represents H or C_{1-6} alkyl;

R^{25} represents H, C_{1-6} alkyl, Het^3 or $-(CH_2)_p$ -aryl (which latter two groups are optionally substituted and/or terminated (as appropriate) by one or more substituents selected from -OH, cyano, halo, amino, nitro, C_{1-6} alkyl and/or C_{1-6} alkoxy);

5 Het^3 represents a five to ten-membered heterocyclic ring containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which also optionally includes one or more =O substituents;
 p represents 0, 1, 2, 3 or 4;

10 or a pharmaceutically acceptable derivative thereof.

provided that:

(a) when D represents either H or -OH, and R^{5a} and R^{5b} both represent H, then at least one of R^2 and R^3 represents OR^7 , $OC(O)R^8$ or C_{1-4} alkyl, which alkyl group is substituted and/or terminated with one or more nitro or cyano groups; and

15 (b) when D represents -OH or $-(CH_2)_cN(R^{10})R^{11}$ in which c represents 0, then:-

(i) A does not represent $-N(R^{23})(CH_2)_j-$, $-O(CH_2)_j-$ or

20 $-(CH_2)_jC(H)(OR^{23})(CH_2)_k-$ (in which k is 0); and/or

(ii) m does not represent 0 when B represents $-(CH_2)_mN(R^{24})-$,
 $-(CH_2)_mS(O)_n-$ or $-(CH_2)_mO-$.

2. A compound as claimed in Claim 1, wherein R^1 represents optionally

25 substituted $-(CH_2)_a$ -phenyl, in which a is 0, 1, 2 or 3, or optionally substituted, optionally unsaturated, linear, branched or cyclic, C_{1-18} alkyl (which latter group may also be interrupted by an oxygen atom).

3. A compound as claimed in any Claim 1 or Claim 2, wherein R² represents H, OR⁷, -CH₂NO₂ or -OC(O)R⁸ or together with R³ represents -O-(CH₂)₂-O-.

5 4. A compound as claimed in any one of the preceding claims, wherein R³ represents H, OR⁷, C₁₋₄ alkyl or together with R² represents -O-(CH₂)₂-O-.

5. A compound as claimed in any one of the preceding claims, wherein R⁴ represents H or C₁₋₂ alkyl.

10

6. A compound as claimed in any one of the preceding claims, wherein R^{5a} and R^{5b} either both represent H or both represent methyl.

15

7. A compound as claimed in any one of the preceding claims, wherein R⁶ represents one or more substituents selected from C₁₋₆ alkyl, cyano, nitro, amino or C(O)N(H)R¹⁹ or N(H)S(O)₂R²¹.

8. A compound as claimed in any one of the preceding claims, wherein X represents O.

20

9. A compound as claimed in any one of the preceding claims, wherein A represents a single bond or linear, or branched, C₁₋₄ alkylene (which group is also optionally interrupted by O).

25

10. A compound as claimed in any one of the preceding claims, wherein B represents a single bond, C₁₋₄ alkylene, -(CH₂)_mO- or -(CH₂)_mN(R²⁴)- (in which latter two cases m is 1, 2 or 3).

11. A compound as claimed in any one of the preceding claims, wherein when D represents $-(CH_2)_cN(R^{10})(R^{11})$, c represents 0, 1 or 2.

12. A compound as claimed in any one of the preceding claims, wherein

5 when D represents $-(CH_2)_cN(R^{10})(R^{11})$, R^{10} represents H, C_{1-4} alkyl, $-C(O)R^{16}$ (in which R^{16} is H, C_{1-3} alkyl or Het²), $-C(O)OR^{17}$ (in which R^{17} is C_{1-5} alkyl, phenyl or C_{1-3} alkylphenyl), $-C(NH)NH_2$ or $-[C(O)]_e-N(H)R^{15}$ (in which R^{15} is H or C_{1-3} alkyl).

10 13. A compound as claimed in any one of the preceding claims, wherein

when D represents $-(CH_2)_cN(R^{10})(R^{11})$, R^{11} represents H.

14. A pharmaceutical formulation including a compound as defined in any

one of Claims 1 to 13 in admixture with a pharmaceutically-acceptable

15 adjuvant, diluent or carrier.

15. A pharmaceutical formulation for use in the prophylaxis or the

treatment of an arrhythmia, comprising a compound as defined in any one

of Claims 1 to 13.

20

16. A compound as defined in any one of Claims 1 to 13 for use as a

pharmaceutical.

17. A compound as defined in any one of Claims 1 to 13 for use in the

25 prophylaxis or the treatment of an arrhythmia.

18. The use of a compound as defined in any one of one Claims 1 to 13 as

active ingredient in the manufacture of a medicament for use in the


prophylaxis or the treatment of an arrhythmia.

19. The use as claimed in Claim 18, wherein the arrhythmia is an atrial or a ventricular arrhythmia.

5 20. A method of prophylaxis or treatment of an arrhythmia which method comprises administration of a therapeutically effective amount of a compound as defined in any one of Claims 1 to 13 to a person suffering from, or susceptible to, such a condition.

10 21. A process for the preparation of a compound of formula I as defined in Claim 1 which comprises:

(a) reaction of a compound of formula II,




15 wherein R², R³, R⁴, R^{5a}, R^{5b}, R⁶, A, B and D are as defined in Claim 1 with a compound of formula III,




wherein L¹ represents a leaving group and R¹ and X are as defined in Claim 1;

(b) for compounds of formula I in which A represents CH_2 and D represents $-\text{OH}$ or $\text{N}(\text{R}^{10})\text{H}$, reaction of a compound of formula IV,



5

wherein R^1 , R^2 , R^3 , R^{5a} , R^{5b} and X are as defined in Claim 1, with a compound of formula V,




10

wherein Y represents O or $\text{N}(\text{R}^{10})$ and R^4 , R^6 , R^{10} and B are as defined in Claim 1;


(c) reaction of a compound of formula IV, as defined above, with a compound of formula VI,

15




wherein L^2 represents a leaving group and R^4 , R^6 , A , B and D are as defined in Claim 1;

5 (d) for compounds of formula I in which D represents H or OH and R^4 represents H, reduction of a compound of formula VII,



10 wherein R^1 , R^2 , R^3 , R^{5a} , R^{5b} , R^6 , A , B and X are as defined in Claim 1;

(e) for compounds of formula I in which one of R^2 and R^3 represents H or OH and the other represents H, reduction of a corresponding compound of formula VIII,



wherein R^1 , R^4 , R^{5a} , R^{5b} , R^6 , A, B, D and X are as defined in Claim 1;


(f) for compounds of formula I in which R^2 and/or R^3 represents $OC(O)R^8$

5 and R^8 is as defined in Claim 1, coupling of a corresponding compound of formula I in which R^2 and/or R^3 (as appropriate) represents OH and a compound of formula VIIIA,



wherein R^8 is as defined in Claim 1;

10 (g) for compounds of formula I in which D represents $-(CH_2)_cNH_2$, reduction of a corresponding compound of formula IX,



wherein c, R¹, R², R³, R⁴, R^{5a}, R^{5b}, R⁶, A, B and X are as defined in Claim 1;

(h) for compounds of formula I in which D represents -N(R¹¹)C(O)NH(R¹⁵),

5 in which R¹¹ and R¹⁵ are as defined in Claim 1 except that R¹¹ does not represent C(O)R¹⁸, reaction of a corresponding compound of formula I in which D represents -N(R¹¹)H, in which R¹¹ is as defined in Claim 1 except that it does not represent C(O)R¹⁸ in which R¹⁸ is as defined in Claim 1, with a compound of formula X,




wherein R¹⁵ is as defined in Claim 1;

(i) for compounds of formula I in which D represents -N(H)[C(O)]₂NH₂, reaction of a corresponding compound of formula I in which D represents -NH₂ with oxalic acid diamide;

15 (j) for compounds of formula I in which D represents -N(R¹¹)C(O)R¹⁶, in which R¹¹ and R¹⁶ are as defined in Claim 1 except that R¹¹ does not represent C(O)R¹⁸, reaction of a corresponding compound of formula I in which D represents -N(R¹¹)H, in which R¹¹ is as defined in Claim 1 except

that is does not represent $C(O)R^{18}$ in which R^{18} is as defined in Claim 1, with a compound of formula XI,



wherein R^x represents a suitable leaving group and R^{16} is as defined in
5 Claim 1;

(k) for compounds of formula I in which D represents $-N(H)R^{10}$ and R^{10} is as defined in Claim 1 except that it does not represent H or $-C(NH)NH_2$, reaction of a corresponding compound of formula I wherein D represents $-NH_2$ with a compound of formula XIA,



wherein R^{10a} represents R^{10} as defined in Claim 1 except that it does not represent H or $-C(NH)NH_2$ and L^1 is as defined above;


(l) for compounds of formula I which are bispidine-nitrogen N-oxide derivatives, oxidation of the corresponding bispidine nitrogen of a
15 corresponding compound of formula I;

(m) for compounds of formula I which are C_{1-4} alkyl quaternary ammonium salt derivatives, in which the alkyl group is attached to a bispidine nitrogen, reaction, at the bispidine nitrogen, of a corresponding compound of formula I with a compound of formula XII,




wherein R^a represents C_{1-4} alkyl and Hal represents Cl, Br or I;

(n) for compounds of formula I in which D and R^4 both represent H, A represents C_{1-6} alkylene, B represents $-N(R^{24})(CH_2)_m-$ and m and R^{24} are as defined in Claim 1, reaction of a compound of formula XIII,



wherein A^a represents C₁₋₆ alkylene and R¹, R², R³, R^{5a}, R^{5b}, R²⁴ and X are as defined in Claim 1 with a compound of formula XIV,

5



wherein R^6 , m are as defined in Claim 1 and Hal is as defined above;

(o) reaction of a compound of formula II, as defined above, with a compound of formula XV,


10



wherein R¹ and X are as defined in Claim 1, in the presence of 1,1'-carbonyldiimidazole;

(p) for compounds of formula I in which one of R^2 and R^3 represents $-NH_2$ and the other represents H, reduction of a compound of formula XVA.

15



wherein R^1 , R^4 , R^{5a} , R^{5b} , R^6 , A, B, D and X are as defined in Claim 1;

(q) for compounds of formula I in which one or both of R^2 and R^3 represent $-N(R^{7a})R^{7b}$ in which one or both of R^{7a} and R^{7b} represents C_{1-6} alkyl, alkylation of a corresponding compound of formula I in which R^2 and/or R^3 represent $-N(R^{7a})R^{7b}$ (as appropriate) in which R^{7a} and/or R^{7b} (as appropriate) represent H, using a compound of formula XXIB,



10 wherein R^{7c} represents C_{1-6} alkyl and L^1 is as defined above;

(r) conversion of one R^6 substituent to another; or

(s) deprotection of a protected derivative of a compound of formula I as defined in Claim 1.


15 22. A compound of formula II as defined in Claim 21, or a protected derivative thereof, provided that when R^{5a} and R^{5b} both represent H, then D does not represent H or OH.

20 23. A compound of formula IV as defined in Claim 21, or a protected derivative thereof, provided that when R^{5a} and R^{5b} both represent H, then at least one of R^2 and R^3 represents OR^7 , $OC(O)R^8$ or C_{1-4} alkyl, which alkyl

group is substituted and/or terminated with one or more nitro or cyano groups.


24. A compound of formula VIII as defined in Claim 21, or a protected derivative thereof, provided that when R^{5a} and R^{5b} both represent H, then D does not represent H or OH.

25. A compound of formula XVII,




10 wherein R^4 , R^{5a} , R^{5b} , R^6 , A, B and D are as defined in Claim 1, or a protected derivative thereof, provided that when R^{5a} and R^{5b} both represent H, then D does not represent H or OH.

26. A process for the preparation of a compound of formula VIII, XVII, XVIII or XXVIII, as defined herein, which comprises reaction of a compound of formula XXIX,



wherein R² represents H or -C(O)XR¹ and R¹, R^{5a}, R^{5b} and X are as defined in Claim 1 with (as appropriate) either:

(1) a compound of formula XXX,



5


or a protected derivative thereof, wherein R^4 , R^6 , A, B and D are as defined in Claim 1; or

(2) NH₃ (or a protected derivative thereof),

10 in all cases in the presence of a formaldehyde.

ABSTRACT

There is provided compounds of formula I,



5

wherein R¹, R², R³, R⁴, R^{5a}, R^{5b}, R⁶, X, A, B and D have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

10

RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS

the specification of which (check applicable box(s)):

is attached hereto

was filed on _____ as U.S. Application Serial No. _____ (Atty Dkt. No.)

was filed as PCT international appl. No. PCT/SE00/01253 on 15 June 2000

and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Prior Foreign Application(s):

Application Number	Country	Day/Month/Year Filed
<u>9902270-9</u>	Sweden	16 June 1999

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

Application Number	Day/Month/Year Filed

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior applications and the national or PCT international filing date of this application:

Prior U.S./PCT Application(s):	Day/Month/Year Filed	Status: patented, pending, abandoned
Application Serial No.		

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And I hereby appoint NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Basha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Paul J. Henon, 33626; Jeffry H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr., 29366; Thomas E. Byrne, 32205; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Jerry D. Craig, 38026; Alan M. Kagen, 36178; William J. Griffin, 31260.

1. Inventor's Signature:

Inventor:

Annika

(first)

MI

Björne

(last)

Date:

31-07-00Swedish
(citizenship)

Residence Address:

Stenungsund, SwedenSEXPost Office Address:
(Zip Code)AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden

2. Inventor's Signature:

Inventor:

Magnus

(first)

MI

Björne

(last)

Date:

07-08-2000Swedish
(citizenship)

Residence Address:

Västra Frölunda, SwedenSEXPost Office Address:
(Zip Code)AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden

3. Inventor's Signature:

Inventor:

Toftbörn

(first)

MI

Halvarsson

(last)

Date:

07-08-2000Swedish
(citizenship)

Residence Address:

Vallda, SwedenSEXPost Office Address:
(Zip Code)AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden

4. Inventor's Signature:

Inventor:

Kurt-Jürgen

(first)

MI

Hoffmann

(last)

Date:

14-08-2000German
(citizenship)

Residence Address:

Kullavik, SwedenSEXPost Office Address:
(Zip Code)AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden

5. Inventor's Signature:

Inventor:

Bertil

(first)

MI

Samuelsson

(last)

Date:

14-08-2000Swedish
(citizenship)

Residence Address:

Skärholmen, SwedenPost Office Address:
(Zip Code)Medivir AB, Lunastigen 7, S-141 44 Huddinge, Sweden

6. Inventor's Signature:

Inventor:

Gert

(first)

MI

Strandlund


(last)

Date:

16-08-2000Swedish
(citizenship)

Residence Address:

Lindome, SwedenSEXPost Office Address:
(Zip Code)AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden

1. Inventor's Signature:	<hr/>			Date:	<hr/>
Inventor:	Annika (first)	MI	Björe (last)	Swedish (citizenship)	
Residence Address:	<u>Stenungsund, Sweden</u>				
Post Office Address:	<u>AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden</u>				
<hr/>					
2. Inventor's Signature:	<hr/>			Date:	<hr/>
Inventor:	Magnus (first)	MI	Björsne (last)	Swedish (citizenship)	
Residence Address:	<u>Västra Frölunda, Sweden</u>				
Post Office Address:	<u>AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden</u>				
<hr/>					
3. Inventor's Signature:	<hr/>			Date:	<hr/>
Inventor:	Torbjörn (first)	MI	Halvarsson (last)	Swedish (citizenship)	
Residence Address:	<u>Vallda, Sweden</u>				
Post Office Address:	<u>AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden</u>				
<hr/>					
4. Inventor's Signature:	<hr/>			Date:	<hr/>
Inventor:	Kurt-Jürgen (first)	MI	Hoffmann (last)	German (citizenship)	
Residence Address:	<u>Kullavik, Sweden</u>				
Post Office Address:	<u>AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden</u>				
<hr/>					
5. Inventor's Signature:				Date:	<u>Sept. 1, 2000</u>
<i>5/00</i>	Inventor:	Bertil (first)	MI	Samuelsson (last)	Swedish (citizenship)
Residence Address:	<u>Skärholmen, Sweden</u> 				
Post Office Address:	<u>Medivir AB, Lunastigen 7, S-141 44 Huddinge, Sweden</u>				
<hr/>					
6. Inventor's Signature:	<hr/>			Date:	<hr/>
Inventor:	Gert (first)	MI	Strandlund (last)	Swedish (citizenship)	
Residence Address:	<u>Lindome, Sweden</u>				
Post Office Address:	<u>AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden</u>				
<hr/>					